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Abstract 
 
The development of information systems used in clinical research is constantly increasing, as 
their advantages are widely acknowledged. Although many researchers have introduced 
information systems which can be used during a clinical study’s process, a scarcity of information 
systems accommodating the complete process has been detected. Based on this finding, twenty-
three (23) information systems and ontologies used in clinical research were retrieved, based on 
certain criteria. The information systems and ontologies were then categorized and evaluated 
based on categorization and evaluation tools. Finally, the result was the synthesis of the eligible-
for-evaluation information systems and the development of a guide for choosing the appropriate 
information system during each step of a clinical trial; the data provided by each information 
system were identified. Unfortunately, some information systems and ontologies were excluded 
from the synthesis due to lack of information regarding the evaluation criteria. Therefore, future 
research should proceed with retrieving this information and developing a guide which will 
consider more information systems, especially for conducting observational studies. 
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 1 
Introduction 
Information technology is widely used in the healthcare sector and the clinical research field has 
made many attempts in order to be part of this innovation. New Clinical Research Information 
Systems (CRIS), i.e., information systems supporting the dataflow during a clinical study’s process 
(Richesson and Andrews, 2019), are continually developed, as their obvious advantages intrigue 
any clinical research organization to implement them. Some of these advantages are improved 
data quality, low costs and more effective management. Moreover, Clinical Trial Management 
Systems (CTMS) are computerized systems responsible for auditing, supporting and reporting 
clinical trials. CTMS should be developed according to specific guidelines introduced by the U.S. 
Food and Drug Administration (FDA), the European Agency for the Evaluation of Medicinal 
Products (EMA) or each country’s equivalent administration (Leroux, McBride and Gibson, 2011). 
The difference between CRIS and CTMS is that CTMS are used specifically in clinical trials and 
support the whole process of a clinical trial. A clinical research information system can be a part 
of a CTMS. 
Clinical Information Systems (CIS), such as Electronic Health Records (EHRs) and Hospital 
information Systems (HIS), are systems used in a health care environment, especially a hospital. 
CIS aim to gather reliable information, use this information for supporting decision-making and 
increase and process this piece of information while it is shared between different clinical areas 
of expertise. Their more important goal is to optimize patient care (Geissbuhler, 1998). In many 
cases, clinical research organizations use Electronic Health Records (EHRs) and Hospital 
Information Systems (HIS) for collecting data which will be used in clinical studies. Therefore, a 
CIS can become part of a CTMS. Although this choice could seem efficient due to its low cost 
(especially in comparison with commercial CRIS), these systems do not fulfil all the prerequisites 
for importing and exporting data in the structure, quality and accuracy necessary for the clinical 
research regulatory requirements (Schreiweis et al., 2014). Therefore, these two systems cannot 
stand alone in managing clinical research data, but they could be the bases for creating new CRIS.   
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Moreover, commercial CRIS are mainly used by pharmaceutical companies. Commercial CRIS 
provide data capture, flow and monitoring based on Good Clinical Practice (GCP) Guidelines, 
automatic reporting and, in some cases, clinical trial management tools (Oliveira and Salgado, 
2006).  Although their advantages make them appealing, they are, also, characterized by some 
technical and functional problems, such as high cost (acquisition and maintenance), high training-
time or even need for specialized personnel, inability to share data freely with each other 
(because of their patented architecture and their incompatible data) and low usability 
(“cumbersome user interfaces”) (Oliveira and Salgado, 2006). Therefore, although 
pharmaceutical companies provide clinical research organizations with commercial systems, the 
clinical studies personnel avoid using them (Oliveira and Salgado, 2006). As the clinical studies 
personnel showed their preference, researchers proceeded with developing information systems 
for supporting clinical studies which will be more usable, scalable, accessible and less expensive. 
In the beginning of this development, CRIS could only support one function of the clinical research 
process, such as recruitment or reporting of adverse events. But as the technology evolved, more 
complicated and multifaceted systems were created (Richesson and Andrews, 2019). However, 
even though the existing CRIS might be able to support more than one function of the clinical 
research process, they still seem unable to support this process end to end.  
This scarcity of a complete CRIS led to the goal of this thesis, which is the development of a guide 
that will assist clinical study management teams in choosing the appropriate CRIS for conducting 
a complete clinical study. First, information regarding the clinical research process and its 
architecture is presented. Then the dataflow in this process is pointed out. Afterwards, a 
literature review of 23 information systems and ontologies used in clinical research are analyzed. 
Finally, categorization and evaluation of these systems are conducted and the CRIS guide for 
carrying out a clinical study is synthesized. 
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Methodology 
Twenty-three (23) information systems and ontologies used in clinical research were retrieved 
via a literature review. The search engine used was “PubMed”. The search-keywords were: 
(“clinical trial*” OR “clinical research”) AND (“information system*” OR ontology). The search 
was restricted by searching only the “Title” for the keywords in order for the results to be more 
specific and accurate. Moreover, in order to collect more up-to-date information, the search was 
restricted to papers published in a specific timeframe: 2000-2019.This search led to 379 results, 
but 344 were papers presenting clinical trials’ reports and therefore, they were excluded. 
Afterwards, the following exclusion criteria were implemented: information systems for 
translational science (because this thesis is not focused on that phase of a medical or 
pharmaceutical innovation) and information systems which consider patient satisfaction and 
patient-reporting (because the evaluation of the CRIS analyzed in this thesis is based on more 
technical characteristics). From the 35 remaining results and their references and citations, 23 
information systems and ontologies were included in this thesis’ analysis and synthesis. For the 
evaluation and categorization of the information systems, another literature review was 
conducted (keywords: clinical information systems; evaluation tool; categorization), and 
evaluation and categorization tools were selected.   
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The Process of Clinical Research 
 
 
The Purpose of Clinical Research 
 
During the last decades, many innovations in the field of healthcare have been introduced and 
clinical trials emerged as the cornerstone of this progress. The results of clinical trials show that 
clinicians and healthcare professionals can use them as a vehicle for improving public health and, 
in the long run, the condition of healthcare systems. Due to the advantages that clinical research 
provides, more information regarding its purpose and process should be discussed. 
 
Definition of Clinical Studies 
Clinical studies are based on research which uses human volunteers/participants and their goal 
is to offer more knowledge to the medical field (ClinicalTrials.gov, 2019). Clinical studies can be 
observational studies and interventional studies or clinical trials.  
The two main goals of observational studies are the testing of the allocation of predictors and 
outcomes in a population (descriptive) and the description of the associations between these 
variables (analytic) (Hulley et al., 2013). Observational studies most commonly take place in cases 
that an investigator cannot apply a randomized controlled clinical trial, e.g., due to ethical issues, 
in rare diseases, etc. (Mann, 2003). Moreover, an investigator might choose to conduct an 
observational study prior to a clinical trial (Hulley et al., 2013).  
Interventional studies (or clinical trials) are conducted in a way that the researcher is allowed to 
intervene during the study (Thiese, 2014). Friedman et al. defined clinical trial as “a prospective 
study comparing the effects and value of intervention(s) against a control in human beings” 
(2015). According to Shankar et al., the purpose of conducting a clinical trial is to test if a drug or 
procedure is safe and effective. Moreover, the process of a clinical trial usually begins after the 
laboratories studies have shown promising results (2006). 
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For a better definition of a clinical study, its life-cycle (steps), phases and designs are presented 
below. 
The Architecture of a Clinical Study 
 
 The life-cycle of a clinical study 
 
According to Sim et al. (2014), a clinical study can be ideally described by five steps/phases (Fig.1): 
(i) refine a scientific question by reviewing and interpreting results of previous studies; (ii) design 
a new study; (iii) carry out the study; (iv) report results; (v) interpret the results and apply them 
to clinical care and policy. These steps complete a circle (life-cycle), because clinical practice (step 
5) will provide information for refining a new scientific question. 
 
 
Figure 1. Idealized scientific lifecycle of a human study within a learning health system (Sim et al., 2014). 
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(i) Conceiving the research question 
The first step of a clinical research project is the conception of the right research question, as it 
specifies the methodology and structure of the research study. (Thabane et al., 2008). According 
to Thabane et al. (2008), the best approach for conceiving the research question is based on the 
PICOT approach (Population, Intervention of interest, Comparator intervention, key Outcomes 
and Time frame) and consists of the following steps: First, the investigator should collect data via 
the scientific literature, e.g., a systematic review made in the research area of the investigator’s 
interest. It is crucial for an investigator to be up to date with the recent discoveries and published 
papers. Second, the PICOT framework should be followed in order to identify what is missing 
from the existing literature, i.e., the researcher should decide on (a) the population of interest; 
(b) the intervention of interest; (c) the comparison with other interventions; (d) the outcome of 
interest; (e) the time needed for the study to be concluded. Third, the PICOT framework is 
followed in order for the research question to be appropriately modelled. Fourth, the investigator 
should estimate if the research question is characterized by the FINER criteria, i.e., the research 
question ought to be feasible, interesting, novel, ethical and relevant; a well-proposed research 
question must be characterized by these epithets (Thabane et al., 2008; Riva et al., 2012; Hulley 
et al., 2013).  
 
(ii) Designing a new study 
During this step, decision support tools are used, and researchers ought to make some decisions 
regarding the appropriate study design type (which will be discussed below), the appropriate 
study population and the identification of biases. As shown in Figure 1, during this step, the study 
protocol is composed. The planned study protocol consists of the activities that should be carried 
out during execution and analysis, while the executed study protocol consists of the activities 
that actually happened (Sim et al., 2014; Hulley et al., 2013). 
The study protocol summarizes and presents the scientific clinical study design (Sim et al., 2014) 
and can be considered an official paper which demonstrates an agreement between the clinical 
investigator conducting the study, the participant/volunteer and the scientific community 
(Friedman et al., 2015). In other words, the study protocol can describe each step that the 
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investigator needs to complete in order to design a clinical study. Friedman et al. (2015) 
suggested the contents of a typical study protocol based on the SPIRIT 2013 Statement, which 
developed guidelines for a clinical trials protocol development (Chan et al., 2013). Therefore, a 
clinical study protocol’s outline as proposed by Chan et al. (2013) and Friedman et al. (2015) can 
be:  
I. Administrative information 
1. Title 
The title must be descriptive and ought to contain the study design, population, interventions 
and trial’s acronym (if applicable). (Chan et al., 2013). 
2. Trial registration 
The trial’s identifier, the trial’s registry number and the “Trial Registration Data Set” (Version 
1.3.1.) as defined by the World Health Organization (WHO) must be provided (Chan et al., 2013).  
3. Protocol version 
Contains the date and version identifier of the protocol (Chan et al., 2013). 
4. Funding 
Presents sources and types of any kind of support (financial, material, etc.) (Chan et al., 2013). 
5. Roles and responsibilities 
This part contains the names of the protocol contributors and study sponsors and the roles and 
responsibilities of every professional participating in the trial (Chan et al., 2013). 
II. Introduction 
1. Background of the study  
This part provides information regarding the research question and the reasons for conceiving it, 
published and unpublished relevant studies and benefits and adverse events of the intervention 
(Chan et al., 2013). 
Adverse events: According to the International Conference of Harmonisation (ICH) of technical 
requirements for registration of pharmaceuticals for human use, adverse event is “any untoward 
medical occurrence in a patient or clinical investigation subject administered a pharmaceutical 
product and which does not necessarily have to have a causal relationship with this treatment”,  
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i.e. an adverse event can be an unplanned and discouraging reaction (sign, disease, symptom) 
related to the administration of a treatment or a drug (1994). 
2. Objectives  
The objectives or hypotheses of the trial are specified (Chan et al., 2013). 
3. Design of the study  
In this part the study design type is provided (Chan et al., 2013) (the study design typology is 
analyzed below). 
III. Methods 
1. Study setting(s) and country(-ies) collecting data for this particular clinical trial (Chan et 
al., 2013). 
2. Study population 
a) Inclusion criteria  
Inclusion criteria issue the basic features of the target population which relate to the research 
question, i.e., age, nationality and race. Many changes might occur while introducing the 
inclusion criteria regarding the geographic and temporal features of the accessible population 
(Hulley et al., 2013). 
b) Exclusion criteria 
Exclusion criteria define the population groups which will not participate in a study, because of 
their inability to adhere to the study’s requirements (e.g., follow-ups) or because they are prone 
to developing adverse effects (Huller et al., 2013).  
3. Sample size 
The number of participants needed for conducting the trial and for achieving its goals/objectives 
is estimated (Chan et al., 2013). 
4. Recruitment/Enrollment of participants  
a) Assessment of eligibility based on the selection criteria (inclusion and 
exclusion) (Chan et al., 2013). 
b) Baseline examination/assessment 
Baseline examination is designed for evaluating a patient’s eligibility for recruitment in a clinical 
study. This examination is the first contact between a physician and a patient/possible volunteer 
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and provides baseline data, which will be used in the next steps of the clinical research process 
Moreover, it should be mentioned that baseline characteristics are the participants’ demographic 
characteristics and baseline measures and data. In general, baseline is the participants’ initial 
status, before the beginning of a clinical study. Therefore, baseline measures can be blood 
pressure measures, cholesterol levels, etc. which were measures before the first intervention 
(Friedman et al., 2015).    
c) Intervention allocation (e.g., randomization method)  
5. Intervention(s)  
a) Interventions for every group participating are described, along with the time 
that these interventions were administered, the method used and the 
professionals administering them. This part is crucial, because it provides the 
ability to repeat the same intervention, if needed. 
b) Criteria for changing or terminating an intervention for a trial participant (e.g. 
changes in the drug dose due to the presence of adverse events). 
c) Strategies for monitoring adherence to protocol and for improving protocol 
adherence, if needed (Chan et al., 2013). 
6. Follow-up visit description and schedule 
Follow-up visit: Follow-up visits can take place after the end of the “original” clinical trial (post-
trial follow-up) and can be continued for decades, as new reactions/effects to a drug or treatment 
can be observed many years after the trial has ended (Llewellyn-Bennett, Bowman and Bulbulia, 
2016). Complete follow-up visits should be promoted (Chan et al., 2013) and follow-up reports 
containing follow-up data ought to be composed (ICH Expert Working Group, 1996). 
7. Data collection methods 
Clinical trial data entry and its quality are planned, along with the study instruments used (e.g., 
laboratory tests). If some data is not presented in the study protocol, instructions/reference for 
finding the collection forms demonstrating them can be found in the protocol (Chan et al., 2013). 
8. Data Management 
In this part of the study protocol, strategies for “data entry, coding, security and storage” can be 
found. Data quality of these processes is promoted (Chan et al., 2013). 
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9. Assessment of Adverse Events  
a) Type and frequency  
There can be a variety of adverse events; they can be minor symptoms, medium reactions or 
major complications. Therefore, adverse events are usually classified based on their severity 
(Hulley et al., 2013). 
b) Instruments (interviews, questionnaires, etc.) 
c) Reporting  
The adverse events that should be reported are unexpected adverse events, expected adverse 
events with an extreme increase in their rate of occurrence, an important risk (e.g. if a treatment 
for a life-threatening disease is proved to be inefficient), etc. (ICH Expert Working Group, 1994) 
10. Data analysis/Statistical Methods 
a) Interim monitoring, including data monitoring committee role (Chan et al., 
2013). 
b) Final analysis: analysis of primary and secondary outcome (Chan et al., 2013). 
For this analysis primary outcome/response variables will be used which will 
answer the research question. Moreover, secondary outcome/response 
variables will provide helpful and supporting information for answering the 
research question (Vetter and Mascha, 2017). 
c) Methods for additional analyses, if needed (Chan et al., 2013). 
d) Statistical methods for managing missing data (Chan et al., 2013). 
11. Data monitoring 
Monitoring of data is a crucial process during a clinical study. Every piece of information entered 
in the study’s system ought to be checked for completeness, consistency (internal and external) 
and currency. If data is inconsistent, it should be corrected. The most error-prone data are the 
dates and times. Moreover, missing data is a typical problem and systems for minimizing this 
problem are necessary (Friedman et al., 2015).  
A Data Monitoring Committee (DMC) is composed and information regarding its role and its 
relation to a sponsor (or not) is provided in the study protocol. In case DMC is not necessary for 
a trial, explanation regarding this decision is presented (Chan et al., 2013). 
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12. Auditing of the way that the clinical trial is conducted 
Audits can be random routine audits, structured audits and audits based on claims about 
scientific misconduct (Friedman et al., 2015). 
IV. Ethics and dissemination 
1. Research ethics approval 
Institutional Review Board (IRB) approval should be administered and therefore, plans for 
receiving the approval are presented in this part of the study protocol (Chan et al., 2013). 
2. Communication of crucial protocol changes to relevant individuals and organizations 
(Chan et al., 2013). 
3. Participants consent/ Informed consent 
A clinical trial’s participants must be aware of their voluntary participation, their role, the 
possibility of unknown risks and discomforts, the possible absence of benefits during and after a 
clinical trial and the way that the protocol works. In other words, participants ought to 
understand that, during a clinical trial, they are not considered a “patient” but a “subject of 
research”. (FDA, 2018). 
Individuals responsible for collecting the consent and individuals authorized to have access to 
participants data are presented (Chan et al., 2013). 
4. Confidentiality 
Ways for collecting and sharing participants data in a confidential way are described (Chan et al., 
2013). 
5. Declaration of interests 
Principal investigators (i.e., the professionals conducting a clinical trial) ought to declare financial 
or other personal and competing interests for the clinical trial or the study settings (Chan et al., 
2013). 
6. Access to data 
Professionals with access to the post-trial data are officially presented. Official agreements from 
investigators with limited data access are, also, presented (Chan et al., 2013). 
7. Post-trial care 
In case of harm, post-trial care is offered to the participants suffering (Chan et al., 2013). 
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8. Sharing policy 
Instructions for sharing data after the end of the trial are demonstrated. In case the study 
protocol can be publicly published, plans for doing so are presented (Chan et al., 2013). 
V. Organization 
1. Participating investigators 
(a)  Statistical unit or data coordinating center  
(b)  Laboratories and other special units  
(c)  Clinical center(s) (Chan et al., 2013). 
2. Study administration 
(a)  Steering committees and subcommittees  
(b)  Monitoring committee  
(c)  Funding organization (Chan et al., 2013). 
VI. Appendices 
1. Informed consent materials 
Official documentation for informed consent (informed consent form) is provided to participants 
(FDA, 2018). This part of the protocol contains model consent forms which should be given to 
participants (Chan et al., 2013). 
2. Biological specimens 
Methods for collection, assessing and storing biological specimens for analysis are presented. 
These methods are important, because they can be used in current and future studies 
researching the same treatment or drug (Chan et al., 2013). 
 
(iii) Study execution 
The tasks included in this step are:  
• Institutional Review Board (IRB) application 
The Food and Drug Administration (FDA) or the European Medicines Agency (EMA) (or each 
country’s responsible agency) establish some specific requirements regarding clinical research 
process and how to conduct one. Based on these requirements, an Institutional Review Board 
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(IRB) is authorized to approve, disapprove or modify a clinical study. The IRB’s goal is to protect 
humans participating in clinical research (FDA, 2019). 
• Set-up study registration 
In order to register a clinical study, five steps ought to be followed: 
a) Define the responsible individual or organization for registering the clinical study 
and which Protocol Registration and Results System (PRS) account should be used. 
b) Be aware of submission requirements. For example, ClinicalTrials.gov allows the 
submission of studies researching biomedical and health outcomes. 
c) Login to PRS (an account with password is used). 
d) Insert the required and optional data elements, which are presented in the PRS 
and are related to the clinical study’s objectives. 
e) Preview, inspect and submit the record and then, verify that the submission is 
completed (ClinicalTrials.gov, 2019). 
• Recruitment and enrollment of patients (according to eligibility criteria)  
According to Friedman et al., “successful recruitment depends on developing a careful plan with 
multiple strategies, maintaining flexibility, establishing interim goals, preparing to devote the 
necessary effort, and obtaining the sample size in a timely fashion”. During this process, it is 
important to find an adequate number of study subjects in a short period of time. The enrolled 
group of subjects (subject samples) is a subgroup of the study population (i.e., individuals sharing 
a condition or some characteristics related to the clinical study’s objectives– inclusion criteria. 
Moreover, the success of the recruitment process is based on the systems used in order to 
identify and select subjects for the participants pool (2015). 
• Protocol execution 
Clinical investigators and other professionals working in a specific clinical study ought to follow 
the instructions provided by the study protocol (as presented above). Therefore, the used 
methodology, definitions and diagnostic criteria are predefined and specific (Friedman et al., 
2015). 
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• Site Monitoring and reporting of adverse events (pharmacovigilance) (Sim et al., 2014).  
Pharmacovigilance: According to the World Health Organization (2002), “pharmacovigilance is 
the science and activities relating to the detection, assessment, understanding and prevention of 
adverse events or any other possible drug-related problems”. 
 
(iv) Report results 
Not only the results must be reported, but the complete study design that brought these results 
must be reported, as well. Moreover, positive and negative results ought to be reported and 
selective reporting should be avoided because it might lead to biased publications. For ethics 
purposes, this phase ought to be unbiased and transparent, as recommended by the Declaration 
of Helsinki (Sim et al., 2014; WHO, 2019; World Medical Association, 2001). The World Health 
Organization has established some requirements regarding the process of reporting clinical trials 
results. First, certain timeframes ought to be followed. More specifically, the first results report 
must be submitted within 12 months after the completion of the trial and, also, their publication 
ought to be public. If public access is denied, specific reasons for this decision ought to be 
presented and the results must become publicly available within 24 months after the completion 
of the trial. This report should contain main findings and key outcomes, such as adverse events, 
baseline characteristics, participant flow (i.e., the participants’ data throughout the clinical study, 
ClinicalTrials.gov, 2018), primary and secondary outcome measures, etc. (WHO,2015).  
 
(v) Interpret the results and apply them to clinical care and policy 
In order for the results to be applied to clinical care and policy, they have to be effectively and 
correctly available. For this requirement to be successful, all study results must be collected in 
certain databases (e.g., journal publications or trial registers) (Sim et al., 2014) and therefore, be 
readily retrieved for further research and policy application. Finally, researchers should be able 
to orchestrate a high-quality systematic review, if needed (Sim et al., 2014). Furthermore, 
clinicians can follow seven steps in order to decide whether they will apply the results of a study 
to clinical care. These steps are:  
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• Understand the clinical study’s hypothesis. 
• Recognize biased outcomes. 
• Confirm that differences between the two groups (control and treatment) are unrelated 
to other prognostic factors. 
• Confirm that the analytical methods used were performed correctly and at an appropriate 
time (once or continually). 
• Confirm that the results were not the product of chance variation. 
• Ensure that the main result demonstrates the superior treatment based on its benefits, 
toxicity, cost and convenience. 
• Clarify the future patients to whom this treatment/drug can be administered (Elwood, 
1980). 
 
It should be mentioned that in some clinical studies, specimens need to be stored for future use 
or in some cases, specimens from previous studies are used for a new one. Furthermore, most 
clinical studies are carried out in multi-site centers and therefore, some requirements need to be 
met. For example, investigators need to have access to follow-up data and patients’ medical 
examinations. Finally, a universal medical and drug terminology is needed for minimizing the 
possibility of “translation” errors between multiple sites (Hulley et al., 2013). 
 
Study design typology 
 
Clinical studies are characterized by different study design types (Fig. 2). The selection of the 
study design is based on several factors: cost, access, the nature of the participant’s exposure to 
the treatment or drug in trial, required epidemiologic measures and currently published data 
related to whatever is researched (Thiese, 2014). The two main categories are observational and 
interventional studies.  
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Figure 2. The study design typology (Sim et al., 2014). 
 
 
Clinical research phases 
 
Clinical studies can also be described by four phases; the quality of every phase depends on the 
quality of the previous one and influences the quality of the next one (Friedman et al., 2015).  
 
• Phase I Studies 
According to the Food and Drug Administration (FDA), during phase I studies, a new drug or 
treatment is tested for the first time in a small group of people (2019). For the first phase of a 
clinical trial, healthy volunteers should be recruited. Another option is the recruitment of patients 
who have the condition tested and have unsuccessfully tried out the already known and used 
treatments. During phase I, researchers aim to find more information over the biopharmaceutical 
aspect of the new treatment/drug, e.g., estimations and data regarding pharmacokinetics, 
pharmacodynamics, tolerability, bioavailability, body distribution and feasibility and safety of the 
delivery systems used. However, the most important finding which ought to be discovered during 
phase I is the “maximally tolerated dose”. The amount of drug safely distributed in the body is 
controlled and decided with several methods (Friedman et al., 2015).  
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• Phase II Studies 
In phase II, the group of people participating in the study increases. The criteria used for selecting 
participants are highly specific and the whole process is done with excessive attention to detail. 
During this phase, the appropriate dosing levels of a drug are established and the effectiveness 
of a drug is tested and therefore, researchers decide if the development of this treatment (or 
drug or device) will continue. In other words, the aim is to assess whether phase III has the 
prospect to be successful or not; this success is the outcome of many factors, e.g., beneficial and 
adverse events (Friedman et al., 2015).   
 
• Phase III/IV Studies 
The goal during Phase III is the estimation of the benefit that the treatment in trial will provide 
to clinical practice and the discovery of the adverse effects occurred by this treatment. Moreover, 
risks of the treatment or drug in trial are evaluated and compared with its benefits and effective 
dosing levels are established. The duration of phase III clinical studies may be long. Researchers 
should consider the importance of the follow-ups after the end of this phase; although many 
tests occur during a trial, a treatment should be investigated for many years afterwards. This 
follow-up investigation is called Phase IV and a large population participates (Friedman et al., 
2015). Phase IV studies are post-marketing studies and the drug or treatment tested is already 
approved by the FDA, European Medicines Agency (EMA) or each country’s responsible agency 
(FDA, 2019). The outcome from a phase IV study will be more accurate because of larger 
populations, actual dosing, longer exposure and long-term follow-ups. Usually, phase IV studies 
are observational studies (Antoniades et al., 2012). 
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Information Needs in Clinical Research 
 
Clinical studies are considered to be information-intensive processes, as much information is 
necessary for the study protocol to be designed and executed. However, attention to the amount 
of information collected should be drawn, as unnecessary data is usually collected and therefore, 
the cost of a clinical trial increases without the corresponding benefits. Moreover, excessive data 
collection can lead to a decrease in data quality (Friedman et al., 2015).  
According to Tran et al. (2011), the clinical research data life-cycle includes three phases: 
• Data specification: Τhe method(s) for storing and collecting data is determined. 
• Data collection via data collection forms, such as the Case Report Form (CRF). These forms 
aim to capture information regarding a patient’s eligibility, status, medical history, 
biochemical data, etc. 
A Case Report Form (CRF) is a significant document used in a clinical research process. The data 
collected in this form is patient data (Bellary, Krishnankutty and Latha, 2014). According to the 
Guideline for Good Clinical Practice, a CRF is “a printed, optical, or electronic document designed 
to record all of the protocol required information to be reported to the sponsor on each trial 
subject” (ICH Expert Working Group, 1996). 
• Data reviewing, reporting and analysis: data entry is checked, and the study’s results are 
reported and analyzed. Moreover, real-time collected data, such as adverse events, are 
reported (Tran et al., 2011). 
Based on the protocol’s needs, Friedman et al. suggested that the data needed for every clinical 
study should include: 
• Baseline information (e.g., selection criteria for determining the study population) 
• Measures of the participants’ adherence to the interventions being tested 
• Crucial concomitant interventions, which refers to other treatments or medications than 
the one in trial that the participants are submitted to (e.g. concomitant medications 
during the trial). 
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• Primary outcome/response variables 
• Secondary outcome/response variables (only the important ones) 
• Adverse events (2015). 
In order for the data collection process to be successful, several sources ought to participate in 
it, such as Electronic Health Records (EHR), paper patient charts, investigator and patient report 
outcomes. Hence, problems during this process can arise. The four basic problems in data 
collection are: missing data, incorrect data, excess variability and delayed submission (Friedman 
et al., 2015). One of the solutions to these problems, as proposed by Friedman et al. (2015), is 
the “Electronic Source Data”; data should be stored in electronic health information systems, 
which will have the ability to integrate. Via this solution, data from various sources will be 
collected, integrated and managed more successfully. 
Gouveia-Oliveira and Salgado suggested that the data needed in a clinical study are related to: 
• Research plan (or study protocol) 
• Clinical Trial Monitoring 
• Laboratory results 
• Treatment allocation 
• Study variables 
• Baseline variables 
• Adverse events 
• Outcome 
• Case Report Form (CRF) 
• Lack of adherence (or discontinuation) 
• Protocol deviations 
• Concomitant treatment/medication (1999; 2006). 
 
Clinical Trial Monitoring: Clinical trial monitoring goals are to confirm that human rights are 
respected, the reported data are complete and accurate and the study is being conducted 
according to the protocol’s instructions, Standard Operating Procedures (SOP), Good Clinical 
 20 
Practice (GCP) and the regulatory requirements. Clinical trial monitoring includes 
study/site/monitoring visits (ICH-GCP, 2019; European Medicines Agency, 2006). 
Study visits are conducted by an investigator or a clinical research coordinator (CRC). During the 
first study visit, the participant is usually informed for the clinical study’s characteristics and 
requirements and signs the Informed Consent Form. Moreover, selection criteria, demographics, 
medical history, concomitant medications, etc. are checked. During the next study visits, vital 
signs, adverse events and blood examinations are usually checked. More generally, during a study 
visit, the investigator or CRC checks for anything important for the clinical study’s process and 
outcome. Furthermore, the investigator or CRC overviews the study and confirms that the 
protocol is being followed and that the personnel is correctly trained according to the protocol’s 
requirements (Friedman et al., 2015; ICH-GCP, 2019). 
Considering the information above regarding the process of observational studies and clinical 
trials and the information needs as suggested by Tran et al. (2011), Friedman et al. (2015) and 
Gouveia-Oliveira and Salgado (1999; 2006), conclusions over the dataflow in this process can be 
drawn. The data needed in every clinical research process can be divided in the following 
categories:  
a) data for selection criteria, sampling and recruitment 
b) data from stored specimens, images, etc. from previous studies 
c) data for adverse events, especially in multi-centered trials 
d) data regarding medical clinical terms and drug terms used globally (standardized 
“dictionaries”) 
e) data found in publications regarding the trial 
f) data from the process and outcomes of old trials 
g) follow-up data 
h) data from the participants’ medical examinations during the trial 
i) data for the statistical analysis (integrated information might be needed).  
As patient privacy and safety is of great importance, all data ought to be managed and accessed 
according to legal and ethical requirements (ICH Expert Working Group, 1996). Moreover, during 
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a clinical trial, information is shared between many procedures, organizations and people of 
interest, e.g., investigators, Institutional Review Boards (IRB), monitoring visits, etc. (Gouveia-
Oliveira and Salgado, 1999). Furthermore, according to Gouveia-Oliveira and Salgado, clinical trial 
monitoring includes detailed documentation regarding Good Clinical Practice (GCP) guidelines 
and study status, records of compliance to the protocol and administrative procedures (1999) 
and finally, the existence of patients’ Case Report Forms (CRFs), which are developed based on 
the trial’s protocol and present all the data recorded and collected during the study (trial activity 
information) (Salgado and Gouveia-Oliveira, 2000). 
 
For all this information to be collected and stored, Clinical Trial Management Systems (CTMS) 
ought to be used. CTMSs support the clinical research process by collecting and integrating data 
from several sources; therefore, the number of errors during a clinical study is decreased and 
communication between clinical research professionals (and participants) is enhanced (Park et 
al., 2018). According to Park et al., CTMSs are responsible for “inputting data, receiving an 
interface through a different system and automatically calculating” (2018). 
Therefore, an information system which will be used in clinical research should be able to input, 
analyze, store and report the clinical study’s data presented above. If the Clinical Research 
Information System (CRIS) cannot support the clinical research information needs, then it should 
be altered, integrated or improved.  
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Information Systems in Clinical Research  
 
 
According to Richesson and Andrews (2019), “Clinical Research Information Systems (CRISs) are 
software applications intended to handle one or more aspects of supporting clinical research”. 
Nowadays, many CRISs are able to accommodate more than one aspect of clinical trials 
(Richesson and Andrews, 2019). However, despite this progress (in the past a CRIS could only 
support one aspect of a clinical study), in order for a clinical process to be completed, more than 
one information systems might be needed. In this chapter, information systems used in clinical 
research are presented and analyzed based on the information needs in clinical research, as 
presented in the previous chapter. 
 
• Tools in a clinical information system supporting clinical trials 
Weisskopf, Bucklar and Blaser (2014) proposed that in order for a clinical information system to 
support clinical trials, some tools should be developed and applied. These tools are: 
§ Clinical information system implemented trial registry and patient-trial-assignment 
Clinical trials ought to be characterized by: study title (complete, short), start date, end date 
(planned), Institutional Review Board (IRB) reference number, principal investigator responsible, 
contact person, alert at hospitalization, short description of the trial, link to the trial, link to trial 
documents, inclusion and exclusion criteria, attachment container for PDF files. Regarding the 
patient-trial-assignment part, in a scenario that a patient is enrolled in another trial, a notification 
appears. 
§ Medical record templates for trial documentation 
For sufficient documentation, the clinical information system provides a trial note form, a 
screening visit form, a follow-up visit form and a form for confirmation that the participant’s best 
interest is sought (the form of confirmation is provided by an independent physician). Data from 
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the registry is integrated in the record templates. The reports are created in a flexible way and 
therefore, they can be used in all types of trials. Moreover, the drug name is reported and 
complete information regarding this drug is included in the report. 
§ Trial and trial subject queries 
Queries regarding the trial can be performed by the management and participants lists of all 
trials, including the participants medical information, can be found via a trial subject query. 
§ Access to electronic medical records 
This access is authorized and only care providers can access the system with their name and 
password. Many levels of access are available, and each level is role-based. 
§ Hospital admission alerts 
If a non-authorized clinician proceeds with a change in a patient’s chart, a notification will be 
sent, because only specific personnel can have full access to a patient’s chart. This notification 
system is important for the patient’s privacy, but also for his/her safety, because a change in the 
chart might be the introduction of an adverse event. 
§ Trial feasibility checks and subject recruitment 
Feasibility checks for the assessment of the number of the eligible patients and subject 
recruitment are accomplished by performing queries in the clinical information system and the 
clinical data warehouse. 
§ Order sets 
Many types of orders are included in these sets. The orders can be simple tasks or complex ones. 
The mix of tasks in each order set can be very detailed or vague and can relate to one another. 
The order sets are named based on the trial or study visit (Weisskopf, Bucklar and Blaser, 2014). 
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After the implementation of these tools, a clinical information system should be able to support 
clinical research. Even though results of the study show that the number of users of this system 
increases, this tool-based clinical information system lacks in scalability. The reason for this 
occurrence is that unless hospitals use the same clinical information system as Weisskopf, Bucklar 
and Blaser used to demonstrate these tools, this tool-based clinical information system is not 
always compatible. Moreover, this tool-based CIS is not automated and patient data safety and 
quality need evaluation (Weisskopf, Bucklar and Blaser, 2014). This tool-based information 
system will be able to support data for recruitment, data for adverse events, data from stored 
specimens, images, etc., data from the medical examinations during the trial and follow-up data.   
 
 
§ Integration of a Clinical Data Warehouse (CDW) and a Clinical Information System (CIS) 
 
Clinical Data Warehouses (CDW) emerged to be extremely useful in the process of integrating 
heterogenous data from different data sources. However, CDWs are not widely used in the 
healthcare sector and therefore, Zapletal et al. (2010) suggested a method for applying a CDW 
integrated with a hospital’s Clinical Information System (CIS). For developing the CDW 
framework, four domains were considered important: 
 
§ The technical realm: The process of data anonymization was the first principle 
guaranteed; the anonymization should be able to be reversed. Structured data were 
extracted from the Hospital Information System, while unstructured data were extracted 
from the Electronic Health Record (EHR) database.  
§ The data realm: After security was guaranteed, real patient data were integrated into the 
CDW in three steps: (i) Identification of data sources, (ii) Mapping of data sources into the 
target schema (target schema: PATIENT, PROVIDER, VISIT, CONCEPT AND OBSERVATION), 
and (iii) Building of dedicated datamarts (for users who need a higher level of data 
granularity). 
§ The restitution realm: Users with different profiles are able to interact with other 
components of the CIS. 
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§ The administration realm: The hospital’s Help Desk became responsible for more 
functionalities, such as the ability to register for a dashboard creation (Zapletal et al., 
2010). 
 
According to Zapletal et al. (2010), the CIS and the CDW should work together and in full 
collaboration; the ClS is responsible for providing the data and the CDW is responsible for using 
this information in order to create new data, such as reports. As Zapletal et al. claim, ultimately, 
this method will benefit: “quality management for auditing or for outcome studies, population 
follow-up, clinical investigations or cases studies and intervention studies (before/after studies 
or controlled trials)” (2010). 
 
 
• A Database System for integrating Clinical Trial Management, Control, Statistical Analysis 
and ICH-Compliant Reporting 
According to Salgado and Gouveia-Oliveira (2000), a clinical trials cycle consists of Patient 
Screening and Registration, Protocol Implementation, Trial Monitoring, Analysis and Publication 
phase. Based on that opinion, Gouveia-Oliveira and Salgado (1999) developed a system 
responding to the International Conference of Harmonization (ICH) guidelines, which includes: 
§ COATI (Control, Assessment and Tracking of Therapeutic Investigations): a system built 
for the monitoring and management of clinical trials. This system/model is based on 
patient’s study visits and is time-oriented (Fig. 3). As the system’s database contains all 
the appropriate data for a study (as presented in the second chapter), analytical tools 
(e.g., DART and PANDA) can be used in order to introduce more applications to the system 
(Oliveira and Salgado, 2006). 
§ Synthesis of the several ontologies needed for coding the outcomes (ICD for related 
diseases and medications (WHO, 2018), WHO-ART for adverse events (WHO, 1984)) 
(Oliveira and Salgado, 1999). 
§ Data Dictionary (Oliveira and Salgado, 1999). 
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§ Statistical Analysis Program (PANDA, DAta ANalysis Package) – PANDA selects patients 
and observations, categorizes the information in the central database, develops data 
marts and creates virtual forms (e.g., tables) which will be used for study reports. “PANDA 
will lead the way for research on stored data in less time and with less effort” (Gouveia- 
Oliveira and Salgado, 1999). 
§ Report generator used for controlling the trial and the reports needed during its process 
(DART, Data Analysis and Reporting Tool) – DART imports data from PANDA, decides over 
the statistical analysis plan and exports its output to PANDA for introducing the final 
report (Gouveia-Oliveira and Salgado, 1999). 
§ A clinical trials reporting system. Reports regarding the participants adherence or 
withdrawal, monitoring visits to the clinical trial’s sites, laboratory results and the study’s 
outcomes are necessary.   
§ A query generation and management system (Q-GEM) – Q-GEM is a software module 
which will allow clinical trials data to be invalid. This parameter is important, because the 
data errors ought to be detected after they have been imported into the system and 
issued in data discrepancy forms (DDF) or data clarification forms (DCF) Gouveia-Oliveira 
and Salgado, 2006). The DDFs/DCFs are documents which include questions regarding 
identified discrepancies in a clinical study (Krishnankutty et al., 2012) and are always 
accompanied by a text-summary regarding the detected problem. Manual intervention is 
permitted whenever a user notices an error not detected by the system. First, the 
DDFs/DCFs are organized by patient and study site, then PDFs are developed and sent via 
email to the study sites or clinical monitors for finding a solution to the problem and 
finally, the user is able to reach directly from the DDF to the respective screen form via 
hyperlinks from Q-GEM to COATI (Gouveia-Oliveira and Salgado, 2006). 
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Figure 3. Top-level Entity-Relationship diagram of the data model of a multiple clinical trials management system (COATI) (Oliveira 
and Salgado, 1999). 
 
Figure 3 represents an Entity-Relationship diagram in which rectangles represent the entities, 
arcs represent associations, a single dash near the entity represents a one-to-one association, a 
circle represents lack of association and a three branched arch represents a one-to-many 
association (Oliveira and Salgado, 1999). 
 
The entities presented are common in all clinical trials, such as previous illness and adverse 
events. This system is based on a study-centric approach (i.e., process-oriented approach) 
instead of a data-centric approach. Hence, it can lead to the development of a generic database 
which will support the data management of any clinical trial. In order for this to happen, each 
study design ought to be modeled into the system via some parameters which encode the 
characteristics of the study design, the research plan and the statistical design. These 
characteristics can be found in the clinical trial protocol and the CRF. The final outcome was that 
the system could provide information regarding more aspects of a trial, such as eligibility 
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verification, data-entry, document management, clinical trial monitoring and site management, 
etc. (Oliveira and Salgado, 2006). 
Via this system, the arrangement of a new trial requires an average of 30-45 minutes; what is 
needed is the definition of the study plan, the eligibility criteria, the study’s medications and the 
baseline and efficacy/outcome variables (Oliveira and Salgado, 1999).  
Information for every patient is available in this system; the format used is similar to the case 
report forms. Afterwards, data collected during the trial for each patient (adverse events, 
laboratory results, adherence to the treatment, monitoring reports etc.) is registered in the 
system (Oliveira and Salgado, 1999). 
Other features of COATI are related to identification of suitable patients for a trial (based on 
eligibility criteria), centralized patient registration and randomization and data-entry from 
remote areas/organizations. Moreover, a great advantage of this system is the access to study 
reports online in real-time (Oliveira and Salgado, 1999). 
In 2000, Salgado and Oliveira, mentioned additional information needed during a trial. For 
example, the system they proposed should be able to distinguish between continuous and 
categorical variables and between different data analysis statistical methods, recognize the 
validity of study visits regarding efficacy and safety analyses and decide over the suitability of 
participants based on eligibility criteria and statistical methods. 
 
• HIS-based patient recruitment: Workflow to improve patient recruitment for clinical 
trials within hospital information systems. 
Patient recruitment is extremely important in the clinical research process. Despite the 
development of several information systems, eligible patients might not be recruited due to the 
study professionals’ vast amount of responsibilities during patient care. Moreover, some 
participants tend to withdraw while the study is still in progress. Dugas et al. (2008) identified 
this problem and suggested the development of a workflow to improve the patient recruitment 
step in clinical trials, while using the already existing hospital information system (HIS) (Fig. 4).  
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According to their workflow, a database query (regarding admission, primary and secondary 
diagnosis, patient age and gender and routine lab values) is created using a HIS’s function: the 
report generator. This query is executed frequently, sometimes once per day, and its outcome is 
compared with the outcomes of prior queries. Afterwards, an automated email is sent to the 
study nurses and physicians as a notification in case a patient is distinguished as a potential trial 
subject. The email does not contain any information regarding the patient’s name, for privacy 
matters. As instructed by the email, the study professional ought to fully access the system and 
select any additional eligibility information; the study professional must be authorized to do so. 
If the patient is eventually considered an eligible participant, s/he is contacted by a study 
physician in order to provide his/her full consent. The actual inclusion and exclusion criteria for 
each patient should be recorded and a trial management tool is responsible to arrange each 
clinical trial’s technical parameters (trial title, data query for each trial, contact information for 
email notification) (Dugas et al., 2008). 
 
Figure 4. HIS-based patient recruitment: an overview (Dugas et al., 2008). 
The results of this case study seem positive. Not only eligible patients were not neglected, but 
the training process of the new workflow was quick, because the users were already familiar with 
the HIS’s functions. Finally, the health information system enabled study professionals to 
preselect patients to participate in specific trials according to their disease status and individual 
features (Dugas et al., 2008). 
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• Single Source Information System 
 
Even though many proposals have been published for using Hospital Information Systems (HIS) 
and their data in order to enrich clinical research data, the information system used is still a dual 
source one (Fig. 5). In a dual source information system, patient care data is collected within the 
Hospital Information System and clinical research data is collected separately in electronic Case 
Report Forms (eCRF) (Dugas et al., 2009).  
 
 
Figure 5. Dual source information systems architecture (Dugas et al., 2009). 
 
As shown in Figure 5, HISs contain information from Clinical Information Systems (CIS), 
Laboratory Information Management Systems (LIMS), Radiologic Information Systems (RIS), etc., 
while research data are collected via electronic Case Report Forms (CRFs). This system leads to a 
vast amount of paperwork and documentation tasks and therefore, Dugas et al. (2009) proposed 
that this system should be developed as a single source information system (Fig. 6). In this 
system, patient care data and clinical research data are both collected in the HIS. However, it is 
important to mention that clinical research data can only be exported from HIS to a different 
research database and only the study data management team will have access to this data. This 
restriction is important, because patient data privacy and security are extremely crucial in a 
clinical research process. Therefore, Dugas et al. (2009) tested their proposed system in an 
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observational study, because in this kind of study, documentation procedures do not need 
validation. Moreover, they tested their system in leukemia trials, but only for patient recruitment 
and only after being approved by the data protection officer (Dugas et al., 2009). 
 
 
Figure 6. Single source information system architecture (Dugas et al., 2009). 
 
To sum up, this single source information system might emerge to be a very useful tool for the 
clinical research field. However, patient data privacy, security and quality are important factors 
in every information system in clinical research and therefore, many changes ought to be made 
and many approvals to be introduced. Moreover, changes in the HIS in order to accommodate 
more functionalities should be made (Dugas et al., 2009). 
• Clinical Research Data Warehouse (CRDW) 
Geibel et al. (2015) suggested the Clinical Research Data Warehouse (CRDW) system. As shown 
in Figure 7, routine data (such as patient data, laboratory results, coded information on diagnoses 
and procedures) are exacted from the Clinical Information System (CIS) and are unified with 
patient information. Via an ETL (extract, transform, load) process, the integrated data are loaded 
into the Clinical Data Storage (CDS), a.k.a., the data warehouse. The ETL process offers three 
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more advantages: it can extract information from unstructured data, pseudonymize structured 
and unstructured data and handle information updates. Information in text-form ought to be 
extracted and therefore, CRDW uses a linguistic pipeline to perform this requirement. First, 
elements from diverse providers must be combined and secondly, the phrases selected from the 
first step ought to be linked to medical terms (“concept mapping”) in a semantic knowledge base 
and be organized into classes. An advantage of using semantic knowledge is allowing queries for 
synonymous terms. Moreover, this system enables the user to utilize the web in order to gain 
access to the database; therefore, clinical trials and their criteria (inclusion and exclusion) are 
described together and former and current patient eligibility is presented together. Regarding 
the clinical trials criteria, it is important for them to be translated into the system’s language 
(terminology and structure) and, also, they will eventually pair with the structured patient data 
and the medical data provided by the linguistic pipeline. According to the case study’s evaluation, 
not many patients were missed during screening; the nurse does not have to check every 
patient’s eligibility status because this is CRDW’s responsibility (Geibel et al., 2015).  
 
Figure 7. Simplified architecture of the CRDW system (Geibel et al., 2015). 
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• ISCO: Information System for Clinical Organizations (Development of the hospital 
information system) 
Bailey and Urqhart identified the information needs in a clinical trials unit in a hospital in Whales 
and provided solutions for improving the clinical trials dataflow process (Table 1). The solutions 
were based on changes and additions in the already existing hospital information system (ISCO). 
This choice was made because of the ability to use ISCO in multisite trials and the lower cost and 
training-time needed for this development in comparison with other proposed systems, such as 
a new stand-alone database. Some of these changes were the development of a tool for 
automatically importing results into ISCO, the inclusion of notes for nurses for every contact (for 
better auditing of clinical trials information), inclusion of activity reports, inclusion of trial 
information into ISCO, inclusion of “required pages” for the data which ought to be collected, 
etc. The proposed information system will improve trials information availability and clinical trials 
accrual (2003). 
Table 1.  Identified problems and their resolutions (Bailey and Urqhart, 2003). 
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The data included in ISCO were expressed in a specific data dictionary of items, which is based 
on ISCO standards, the NHS Data Dictionary (NHS, 2019), the Welsh NHS Data Dictionary (NHS 
Wales, 2017) and the entity-relationship model (ERM) in Figure 8. A trial’s information can be 
categorized in two types: patient-specific data (e.g., study number, reason for not enrolling, 
reason for withdrawal, date registered/randomized, etc.) and trial-specific data (e.g., data 
approved by ethics committee, title, acronym, etc.). The latter can be categorized as trial 
documentation (stored in HTML) and data required for trial management (stored in ISCO). 
Afterwards, each user requirement was added in ISCO according to prioritizing criteria, such as 
the urgency and the workload for this addition. A crucial step was the establishment of reporting, 
because data warehouse prototypes were already being built. The entity relationship model 
(ERM) in Figure 8 presents the required reports and data items and the ISCO structure (Bailey 
and Urqhart, 2003). 
 
 
Figure 8. Entity relationship model for clinical trials in ISCO (Bailey and Urqhart, 2003). 
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[hcor (healthcare organization), hcpo (healthcare professional-organization link table) and hcpi (healthcare professional) tables 
were included for storing addresses and coding information for healthcare professionals and organizations (Bailey and Urqhart, 
2003).] 
For the implementation and evaluation of this information system, prototype data entry screens 
were designed and approved by users, tables within ISCO and trial documentation in HTML were 
introduced, retrieval of data entry and trial documentation was arranged, user approval was 
examined and evaluation after the implementation (and benefit analysis) was carried out (Bailey 
and Urqhart, 2003). 
Unfortunately, this suggested information system cannot easily be generalized to other hospitals, 
as not all clinical trials units are located in specialized hospitals and some of them need 
administrative data management for multisite clinical studies and therefore, more advanced 
information systems (Bailey and Urqhart, 2003). However, the inclusions made within ISCO 
represent some information needs that many clinical studies have. For example, information for 
the clinical studies being conducted in a hospital is vital for their successful outcome. Moreover, 
data from study visits should be electronically collected in every clinical study, because manually 
created documents can be lost or incomplete. Therefore, the information system suggested by 
Bailey and Urqhart (2003) seems to be very useful for meeting the clinical research information 
needs. 
§ Adverse Event Data Management System (AEDAMS) 
As mentioned above, “pharmacovigilance is the science and activities relating to the detection, 
assessment, understanding and prevention of adverse events or any other possible drug-related 
problems” and many regulations and requirements have been established in order to audit 
pharmacovigilance, especially in clinical studies (WHO, 2002). Richesson et al. (2008) recognized 
the information needs regarding adverse events (AEs) spawned during clinical trials. While aiming 
to the correct and trustworthy audit of adverse events in clinical trials, Richesson et al. (2008) 
introduced the Adverse Event Data Management System (AEDAMS). AEDAMS offers many 
advantages to the clinical research process, such as a more standardized procedure of reporting 
noted adverse events in different sites during a multi-sited study and the customization of unique 
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protocols, while saving time (reporting, transferring to other sites and training time) and money 
and succeeding in quality controls. This automated approach can be efficient and easily adaptable 
to different study designs, trial phases and disease areas. This information system is able to 
collect, track, manage and communicate data regarding AEs. The AEDAMS can be described by 
its three components (Fig. 9): 
 
 
Figure 9. Flowchart of adverse events (AEs) handling in Adverse Events Data Management System (AEDAMS) applied to a clinical 
research network. DSMB: Data Safety and Monitoring Board; DTCC: Data and Technology Coordinating Center; PI: Principal 
Investigator (Richesson et al., 2008). 
 
i. Administration and Configuration of the System 
The system consists of three main roles:  
• the AE administrator, who is responsible for the system’s assignments, notifications and 
access validations,  
• the AE reporter, who is responsible for allowing the appropriate research staff to report 
and update the system with AE information, 
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• and the AE reviewer (medical monitor), who is informed about reported AEs and any 
updates regarding AE information; s/he, also, reviews all the data in order to introduce 
comments and recommendations for a study’s course (i.e., changes or even termination). 
The AE administrator is offered the flexibility to interfere manually to the assignment of the AE 
reporter and reviewer roles and change their responsibilities correspondingly to their availability, 
schedule and possible delay (Richesson et al., 2008). 
 
ii. AE reporting 
If an adverse event occurs, the AE reporter accesses the patient’s study data and reports the 
adverse event in a standardized reporting form. The AE reporter provides information regarding 
the noted AE and either submits the form or saves that piece of information and comes back to 
it later for editing the data. Because of this function, research staff can make a note on an adverse 
event and wait until their suspicions are ascertained to declare them. In the above-mentioned 
form, AEs are categorized corresponding to their origin/field and severity and information for any 
changes in the AEs report is included; if an AE reviewer edits a reported event, then the reasons 
for each change and any additional information ought to be presented in the original report 
(Richesson et al., 2008). 
 
iii. AE review – Monitoring  
The review criteria used from AEDAMS for reported AEs are seriousness and expectedness. 
Information for each patient is presented as a whole and each reported AE is accompanied with 
a status, such as open events (not assigned yet), events awaiting review (assigned, but not 
reviewed) and closed events (reviewed). The system offers the convenience of selecting a 
separate tab button for viewing each status category. After the reviewer has completed his/her 
part (e.g., assign causality: define the reason for the appearance of an adverse event), the final 
review will be checked by individuals with the responsibility of the “notification after review” 
role, such as the study chair, site investigators, study sponsors, etc. AEDAMS secures its database 
and enables the auditing of any new data related to reported AEs (Richesson et al., 2008). 
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Finally, Richesson et al. (2008) also mentioned that AE management systems, such as AEDAMS, 
can be used as electronic records and provide electronic case report forms (e-CRFs). This function 
will lead to a more efficient audit of data entry, communication and updates. 
• Active Computerized Pharmacovigilance using NLP, Statistics and EHRs (Drug-AE 
detection system). 
 
Wang et al. (2009) proposed a system that can detect new adverse events. In comparison with 
Richesson et al. (2008), this system was based on the already existing Electronic Health Records. 
As they mention in their article, there are some crucial adverse events (AEs) which are usually 
found in the unstructured (narrative) parts of EHR reports. After realizing this fact, Wang et al. 
(2009) developed a framework which will provide automated active pharmacovigilance and is 
based on natural language processing (NLP), statistics and unstructured clinical data found in EHR 
systems. Their framework (Fig. 10) can be divided into five phases and its final goal is to detect 
any drug-AE associations from narrative reports. 
 
i. Phase 1: Data Collection 
In the beginning, narrative reports, coded laboratory data and pharmaceutical orders are 
collected (structured and unstructured data should be collected). 
 
ii. Phase 2: Data Extraction 
The next step is to encode clinical entities found in the collected reports. For this procedure, NLP 
is used. More accurately, in order to analyze discharge summaries and present them as 
structured data the MedLEE system is used. 
 
iii. Phase 3: Data Selection 
For selecting entities which can possibly be AEs, the UMLS codes extracted in phase 2 correspond 
to the following semantic classes: Finding, Disease or Symptom, Mental or behavioral 
dysfunction, Sign or symptom and Neoplastic process. 
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Correspondingly, for selecting medication entities the semantic classes are: Pharmacologic 
Substance, Antibiotic and Clinical Drug. 
 
 
Figure 10. Overview of System Framework (Wang et al., 2009). 
 
iv. Phase 4: Data Filtering 
In order to eliminate some clinical entities, two main and one contextual filters are used. Filter 
No1 eliminates entities associated with modifiers related to some certainty values (e.g., low 
certainty), past events, or family history events. Filter No2 eliminates chronologically wrong drug-
indication timelines. The contextual filter confirms that the order of events is chronologically 
correct. 
 
v. Phase 5: Drug-AE Association 
In order to reveal drug-AE associations, potential drug-AE pairs were developed by employing 
statistics (Wang et al., 2009). 
This information system has the power to automatically detect new adverse events by using only 
the existing information in EHR systems; only few arrangements are needed (NLP and statistics). 
In the future and as the creators of this system suggest, it might enable the combination of 
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structured and unstructured data. However, some precautions should be considered when this 
system is used. For example, treatment indications should not be confused with adverse events; 
sometimes a drug is used in the later stages of an illness and the symptoms that might be 
observed during its administration might only be the result of the illness’s progression. Moreover, 
other limitations are presented in Wang et al.’s paper (e.g., narrative reports were collected only 
from inpatients or not appropriately defined UMLS codes) and therefore, more research on this 
system should be done (Wang et al., 2009). 
• National Clinical Trials Registry 
McGray and Ide recognized a “gap” in the literature regarding information systems for clinical 
trials; the existing systems centralize the need for access to clinicians and researchers, while 
access to patients and other public groups is neglected (2000). Therefore, designing their system 
began with guarantying that the patients’ needs were identified. Their next steps were to 
implement a standard syntax and semantics for the data of interest and to realize that the system 
should be built in phases, as more requirements would surface during the system’s development. 
As the World Health Organization requires clinical studies reports to be publically available 
(WHO, 2015), one of their primary goals was to build a system understandable to the public. 
Therefore, they developed an accessible and easily operated Web-based system for patients to 
express their queries. The first trials to be introduced to the system were trials sponsored by the 
National Institute of Health (NIH) and McGray and Ide agreed with the trials providers to a 
common set of data elements (required and optional) which will be used for the clinical trials 
data (McGray and Ide, 2000). The required and optional data elements are shown in Table 2. 
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Table 2. Required and Optional Data Elements (McGray and Ide, 2000). 
 
According to this system, the recruitment status can be: not yet recruiting, recruiting, no longer 
recruiting, completed, suspended and terminated. Moreover, the study types (9) recognized by 
this system are: diagnostic, genetic, monitoring, natural history, prevention, screening, 
supportive care, training and treatment.  Whenever is feasible, the intervention and condition 
studied in each trial is provided via the Medical Subject Headings (MeSH) of the UMLS (Unified 
Medical Language System); an exception to this rule can be the case of a new drug which is not 
included in the MeSH yet. Furthermore, the references of publications should be delivered by the 
study providers with a unique identifier (UI) which will be linked by the system’s creators to a 
MEDLINE citation record (McGray and Ide, 2000). 
Every record introduced to the system is characterized by a specific and unique number, which 
operates as the identifier of the trial. The data from each provider is included in the system’s 
central database at the National Library of Medicine (NLM). McGray and Ide(2000) offered help 
to institutes that wanted to redesign their databases in order to provide more standardized data, 
and even to those that did not need assistance, the system’s creators provided their services 
before the final confirmation of the data. Finally, each report ought to be sent to the system in 
extensible markup language (XML) format correspondingly to the created document type 
definition (DTD) (McGray and Ide, 2000). The DTD created by McGray and Ide (2000) contains 
data regarding the study title, study sponsor, a brief summary of the study, the start and end 
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dates, the intervention type, etc. This choice was made because of the XML’s advantage to be 
understandable by both humans and computers (McGray and Ide, 2000). 
The final outcome of this design is the collection of NIH-trials records and their storage in a 
centered database at NLM. The dataflow during the implementation of this system is shown in 
Figure 11. The provider regularly sends XML formatted reports to NLM via file transfer protocol 
(FTP) and the system proceeds with data validations whenever an update is sent from a provider. 
Afterwards, the validated data is expanded with condition names (from a list of disease 
categories), literature references, links to MEDLINEplus and NLM’s consumer health site. After 
this process, the data is made available on the Web and therefore, to the patients. Finally, the 
retrieval engine is responsible for processing users’ queries; the engine inspects for spelling 
errors, expands the query and develops HTML for Web browsers (McGray and Ide, 2000). 
 
Figure 11. System Design (McGray and Ide, 2000). 
 
During data preparation, the data flow is as shown in Figure 12. The data is received as XML 
documents (“received area”), they are checked for structural errors (“validated area”), they are 
enriched in order to enable a “browse-by-condition” process (“enhanced area”) and finally, the 
clinical studies database is built with the collection of clinical trials’ data and a vocabulary 
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collection (“publisher process”). After the end of the data preparation, the database is ready and 
accessible by the retrieval engine (McGray and Ide, 2000). 
 
Figure 12. Data preparation subsystem (McGray and Ide, 2000). 
 
• OpenTrials 
Goldacre and Gray (2016) discussed the OpenTrials project and its Phase I development. Via this 
project, information regarding clinical trials registered in different databases/registers and 
diverse structures will be able to be combined, compared and accessible to researchers, 
academic and healthcare personnel, patients and clinical research related organizations. This 
information system aims at the creation of an open database and the sharing and analysis of 
information regarding clinical research. As shown in Figure 13, clinical trials data are extracted 
from: 
§ Registers (industry registers: for trials carried out by a company; national registers: for 
trials carried out by one regulator or in a specific location): different registers might 
contain different information for the same clinical trial and these differences should be 
noticed and clarified. 
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§ Academic journals: they offer information in several document types (e.g., protocols) and 
in semi-structured free text form. Also, an ID number can pair an academic journal article 
with a registry entry. 
§ Regulatory Documents: they present information in a defined structure or in a free text 
form. 
§ Structured Data: they can be retrieved via registers and manually extracted data from 
free text reports of systematic reviews (e.g., from SRDR – Systematic Review Data 
Repository).  
§ Trial Paperwork: information can become available via several forms (blank consent form, 
blank case report form, patient information sheet, etc.), protocols, lay summaries and 
statistical analysis strategies (Goldacre and Gray, 2016). 
 
Figure 13. Overview of OpenTrials data schema and information flow (Goldacre and Gray, 2016). 
 
The database needed for this information system can be created by several techniques, such as 
“importing publicly accessible structured data, web-scraping (for accessible, but not available for 
download data), record linkage (a matching data technique) and curated, targeted 
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crowdsourcing and donations of structured data”. Unfortunately, the database development 
(inclusion of data from all clinical trials conducted or being conducted) is a very expensive 
procedure and the project’s funding is limited and therefore, this development will proceed step 
by step and with the above-mentioned techniques (Goldacre and Gray, 2016). 
Despite the advantages that this system provides, problems regarding its application can be 
noticed, as well. For example, in order for the combination of different data from different 
sources to be introduced into one database, a common “dictionary” ought to be developed and 
applied. Goldacre and Gray (2016) decided to solve this problem by introducing wide data-
categories based on the list of sources mentioned above (registers, academic journals, regulatory 
documents, structured data and trial paperwork). By following this approach, different ways of 
addressing structured data are included and therefore, data with multiple formats can be 
managed and interpreted. Specifically, what Goldacre and Gray (2016) created is a “thread of 
documents on a given trial”; a document can be an actual document, such as an informed 
consent, or structured data, e.g., data from ClinicalTrials.gov, such as reported results of clinical 
trials, reported adverse events and all the information provided in a clinical study’s protocol, as 
presented in the first chapter (Goldacre and Gray, 2016). 
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Ontologies and Ontology-based Information Systems in Clinical 
Research 
 
 
Clinical research is an information-intensive field and in order for its outcome to be valid, 
accurate and complete, the information needed should be collected via several sources. This “key 
requirement” for successful data collection, integration and harmonization is difficult to be met. 
Hence, the development of ontologies supporting the clinical research, as well as, ontology-based 
clinical research information systems seems to become more and more necessary. The ultimate 
goal is to create a connection between the many ontological resources found in health care sites 
(Richesson and Andrews, 2019).  
The use of ontologies in data representation during a clinical study can offer many advantages, 
such as successful integration of data, increase in the published literature and database and 
reusability of research data (Smith and Scheuermann, 2011). Ontologies can benefit every step 
of a clinical study; they can describe a study’s design, represent study metadata deriving from 
several sources (e.g., Electronic Health Records or Clinical Report Forms), enable selected tasks 
during a study’s execution, capture eligibility criteria and identify new patients as eligible 
participants, help investigators to detect a study’s strengths and weaknesses and to interpret 
them along with the study’s results (Sim. Et al., 2014). Therefore, ontologies and ontology-based 
information systems used in clinical research are analyzed in this chapter. 
 
• Epoch: an ontological framework to support clinical trials management 
The goal of the creators of Epoch was to build an ontological framework which will be able to 
follow-up participants throughout the duration of a clinical studiy and clinical specimens tested 
at trial laboratories. During a clinical study, numerous tests and examinations are conducted. 
Therefore, following-up participants in order to assure that these tests are complete and to select 
and report their results is an important part of a clinical study. Epoch (Fig. 14) is developed in 
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order to be used for the management of multi-site clinical trials carried out at the Immune 
Tolerance Network (ITN), as it will “collect, manage, integrate and analyze clinical trial and 
immunoassay data” (Shankar et al., 2006). Although many activities are considered a part of 
clinical trials management, Shankar et al. (2006) focused only on two of them for building Epoch: 
(a) participant tracking and (b) specimen tracking.  
Their knowledge-based framework was developed based on three types of methods: 
A. Development of a number of ontologies for a more accurate specification of knowledge 
on immune disorders.  
B. Ontology-database mapping methods which will merge the study metadata and 
biomedical knowledge base with stored primary data in the data repository. 
C. Concept-driven querying methods via which the data repository will accommodate 
integrated data management and high-level data analysis projects (Shankar et al., 2006). 
Epoch consists of more than one ontology: 
 
i. The Clinical Ontology, i.e., a terminology of the clinical and biomedical discipline 
regarding immune tolerance disorders. 
ii. The Protocol Ontology, i.e., a model focused on the protocol concepts of participant 
and specimen tracking; hence, the protocol schema (information for the phases of a 
trial and their chronological sequence) and the schedule of events (the timing and 
events of a study visit) are represented in this ontology. 
iii. The Specimen Ontology, i.e., the modelling of specimens’ workflow (collected in a site 
– transferred to bio-repositories – transferred to core laboratories where results are 
analyzed– stored and analyzed in a data warehouse). 
iv. The Site Model, i.e., a structure for storing site-related data (e.g., protocols, 
participants, study coordinators, etc.). 
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v. The Specimen Container Ontology, i.e., a list with information regarding all specimen 
containers and each one’s characteristics (e.g., size, manufacturer, additives, 
material, shipping instructions, etc.). 
vi. The Virtual Trial Data Ontology, i.e., a summary of the collected data during the study, 
such as specimen workflow records and participants’ clinical records (Shankar et al., 
2006). 
 
 
Figure 14. Epoch: An Ontological Framework to support Clinical Trials Management (Shankar et al., 2006). 
 
Other activities needed for the development of Epoch, besides the protocol schema and the 
schedule of events, are the specimen table and specimen flow. The specimen table provides 
information regarding the specimens collected for each participant, as well as their analyses. The 
specimen flow’s function is to provide information regarding the processing of the specimens, as 
mentioned above (Shankar et al., 2006). 
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For the Epoch ontological framework to provide knowledge-based reasoning and query methods, 
its development is based on several interacting elements (Fig. 15). The Epoch Knowledge Base 
provides the ontologies described previously, the Knowledge Base Server provides an application 
program interface (API) for permitting access to other sections to the ontology repository, the 
Clinical Trial Database stores data created from the implementation and execution of a clinical 
trial (included data: participant enrollment data, visits and activities, specimen shipping and 
receiving data and clinical results) , the Model-Database Mapper, based on a mapping ontology, 
enables access to the Clinical Trial Database  for relational data, the Inference/Rule Engine carries 
out constraints in Epoch ontologies, the Utility Functions enables import and export of the 
knowledge base and finally, the Clinical Trials Management Applications (such as “authoring 
tools, operational plan builders, study site management tools, participant and specimen tracking 
applications, and trial data analyzers”) work with the Epoch components in order to support the 
clinical trials management (Shankar et al., 2006). 
 
 
Figure 15. A high-level functional architecture of the Epoch framework (Shankar et al., 2006). 
 
• OnWARD: Ontology-driven web-based framework 
 
After setting as a goal to create a secure, high-quality and flexible framework, Tran et al. (2011) 
proposed OnWARD for a Phase II clinical study called HeartBeat (Heart Biomarker Evaluation in 
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Apnea Treatment). This Ontology-driven web-based framework is a combination of three 
components: Data Specification (DS), Data Capture (DC) and Data Exploration (DE); these 
components are the three phases of a clinical study’s data life-cycle and are integrated under a 
clinical research ontology. Once more clinical studies will use OnWARD, this clinical research 
ontology will be expanded (Tran et al., 2011). The functionality of each component is described 
below:  
 
§ Data Specification (OnWARD-DS): this element provides to the investigator the 
opportunity to choose the way for storing and collecting data. In order for data 
specification to be complete, a backend relational database is selected, and each clinical 
study connects with this database and proceeds with data entry, retrieval, validation, etc. 
with the help of the other two components. 
§ Data Capture (OnWARD-DC): OnWARD-DC is a “dynamic form generation engine” which 
will provide to the system a variety of different, flexible and changeable forms. These 
forms will contain data in several structures (e.g., free-text, numeric responses, etc.), 
which will be based on the metadata chosen from OnWARD-DS and on the clinical 
research ontology. 
§ Data Exploration (OnWARD-DE): OnWARD-DE participates in the input validation process, 
during which data entry is checked. This process also uses the clinical research ontology 
used by the system and validates data in three pillars: (i) Data type, (ii) Hard range 
validation and (iii) Soft range validation. Moreover, another function OnWARD-DE 
provides is “skip patterns”: data entry is adjusted according to the way that previously 
asked questions were answered. Finally, OnWARD-DE benefits the clinical study process 
by enabling researchers to develop reports regarding a clinical study and to search for 
reports of a study of interest; hence, patient recruitment becomes more efficient (Tran 
et al., 2011). 
 
The results from the evaluation of this system/framework showed that not only the advantages 
in finding eligible participants are obvious, technical advantages can be observed, as well. First, 
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training-time was low, and usability was high. Second, the system will be able to accommodate 
clinical studies of different sizes (from small to medium). Third, OnWARD can support 
randomization. Last, this Ontology-driven web-based framework can be characterized by data 
quality and security (Tran et al., 2011). 
• A semantic interoperability layer 
 
Alonso-Calvo et al. realized the need for minimizing the heterogeneity of data originating from 
distributed centers in multi-sited clinical studies. As a solution to the existing, manual and error-
prone approach, they proposed a method for automatically integrating heterogenous data by 
introducing a Common Information Model (CIM), which will be the outcome of the integration 
and homogenization of information from Clinical Trial Management Systems (CTMS), Laboratory 
Information Management Systems (LIMS), Electronic Health Record (EHR), etc. The CIM will be a 
combination of a Common Data Model (CDM) and a Core Dataset (CD) (Fig. 16) (2015). 
 
Figure 16. Semantic Interoperability Layer (Alonso-Calvo et al., 2015). 
• Common Data Model (CDM): The CDM will be responsible for homogenizing information 
system data models from several institutions or from an institution’s different 
departments 
• Core Dataset: The CD will be able to provide a vast amount of clinical terminologies found 
in several data sources and scenarios.  
• Terminology Builder: Another component of this system is the Terminology Binding which 
will determine relations between CDM and CD. For developing the Terminology Binding, 
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three steps should be followed: vocabulary integration, binding annotation and 
disambiguation. Finally, for retrieving data from this system, SPARQL queries are 
executed (Alonso-Calvo et al., 2015). 
This semantic interoperability layer will be used for recruitment and screening of patients based 
on eligibility criteria and for retrospective analysis of multi-centered clinical trials. This system 
will eventually be improved by implementing authorized access and therefore, becoming more 
secure and legal (Alonso-Calvo et al., 2015). 
 
• The Linked2Safety project: Using distributed Electronic Health Records (EHR) with 
different legal and ethical requirements. 
 
According to Antoniades et al. (2012) the Linked2Safety project was initiated because of the 
growing need of using distributed Electronic Health Records (EHR) with different legal and ethical 
requirements for several healthcare reasons, e.g., clinical trials recruitment, identification of 
adverse events, increase in the statistical power of data analyses, etc. Although a combination of 
EHRs from different organizations is a helpful solution whenever merged data are needed, 
limitations in this procedure exist due to the legal and ethical implications of patient privacy. In 
order to overcome these limitations, Linked2Safety was suggested (Fig. 17) (Antoniades et al., 
2012). 
As the main goal of this system is the preservation of legal and ethical requirements, a “closed-
world” room is introduced, in which EHRs are processed in a network-connection-free 
environment. In this room, only authorized personnel have access. During the aggregation of 
data, Linked2Safety will provide options for the appropriate ways of analyzing and combining 
data; because of this function, problems regarding the ethics and laws of aggregating data are 
minimized. The program proceeds with a quality control, aiming to identify possible ways of 
connecting the data to a subject or a group of subjects. By doing so, the system provides means 
to prevent such connections. Finally, only aggregated data will be eligible to be transferred 
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outside the “closed-world” room and become a part of the rest of the Linked2Safety platform 
(Antoniades et al., 2012). 
 
 
Figure 17. The Linked2Safety Platform (Antoniades et al., 2012). 
 
This procedure will be followed by each site maintaining clinical data. If some definitions overlap, 
then they are recorded and combined by the Linked2Safety platform and as a result, the 
statistical power of the outcome increases. By the end of this process, the data will be available 
to researchers and other healthcare professionals with access to the Linked2Safety platform 
(Antoniades et al., 2012). 
This project will eventually decrease the expenses of clinical trials, because sites and subjects will 
be readily identified as appropriate for a clinical trial, as described below. Another advantage 
that the Linked2Safety platform will offer is the ability of analyzing aggregated data with 
methodologies which were not developed or considered when the data were collected in the 
first place; therefore, this ability will make the use of old data for new clinical studies easier and 
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more possible. In order for this ability to be created, multidimensional data cubes will be used. 
The Linked2Safety project seems to be able to offer its help to many procedures during a clinical 
study. However, three functions were introduced by Antoniades et al. (2012):  
i. Recruitment/Selection of Subjects for Phase III Clinical Trials 
This step is a costly and time-consuming procedure. Moreover, it should be mentioned that 
Linked2Safety will help the recruitment in multi-centered clinical trials and in the scenario that 
investigators and academic research organizations search for physicians who carry out specific 
clinical trials with patients meeting specific eligibility criteria. 
ii. Post Marketing Surveillance Trials (Phase IV) 
During Phase IV trials, Linked2Safety will offer information over adverse events presented in 
several and distributed sites along with data, such as demographics and data on medication used 
and treatment performed. Therefore, factors causing these adverse events and challenging 
safety will be noticed and certified as soon as possible. 
iii. Identification of Relations between Molecular Fragments and Specific Adverse Side 
Effects Categories (Chemoinformatics) 
Linked2Safety is able to identify possible relationships between chemical structures of drugs and 
adverse events. For this process to work, a vast amount of information regarding patients and 
their drug treatments ought to be available and readily accessible (Antoniades et al., 2012). 
 
• ODaCCI: Ontology-guided Data Curation for Multisite Clinical Research Data Integration 
 
Cui et al. introduced ODaCCI as an ontology-guided approach for supporting the Informatics and 
Data Analytics Core (IDAC) curation strategy of CSR (Center for SUDEP research; SUDEP: Sudden 
Unexpected Death in Epilepsy). This approach was conducted due to the CSR’s challenges, such 
as data heterogeneity (an Ontology-driven Patient Information Capture system – OPIC – will 
decrease the heterogeneity), data access restriction, multimodal data linkage and data quality. 
These challenges are the result of the need for integrating data from the distributed sites of multi-
centered clinical studies (2016). 
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The ODaCCI architecture is shown in Figure 18 and the steps for developing this system are the 
following. First, identifiable information (patient phenotype data) from each site is inserted into 
the OPIC system. Second, via an automatic (by OPIC) and manual (by personnel) de-identification 
process, the information in the OPIC system becomes de-identified. Then, the de-identified data 
will be available in the CSR central repository. Third,  the de-identified data from each site are 
transferred to a database in the central repository which is connected with the data curation 
system (the ODaCCI) and therefore, an expert will be able to audit and curate the data; the 
curated data will be stored in a separate database which will store only curated data (Cui et al., 
2016). 
 
 
Figure 18. The Ontology-guided Web-based Data Curation System (ODaCCI) architecture (Cui et al., 2016). 
 
The ODaCCI consists of six sections: 
§ Common data elements (CDEs): CDEs are common data found in every clinical site and 
the data sources were chosen by experts in the epilepsy domain. This data will be 
integrated. 
§ Ontology-based vocabulary: The ontology used is the Epilepsy and Seizure Ontology 
(EpSO). 
§ CDE to data source mappings: The CDEs from the different clinical sites might not be the 
same, because different versions of OPIC might be used in these sites. Hence, the data 
ought to be mapped to the data dictionary’s data tables and columns. 
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§ Dynamic generation of data curation widget: This widget is a web-based data curation 
interface used during the manual curation of data. 
§ Dynamic Generation of MySQL statements: They are used for saving the changes that 
domain experts make. 
§ Data auditing measures: These measures are actually data quality measures and are 
completeness and consistency (Cui et al., 2016). 
ODaCCI’s aim is to provide integrated, high-quality and secure data from distributed clinical trial 
sites. As a result, recruitment SUDEP research was increased. Lastly, it should be mentioned that 
ODaCCI is a scalable system, due to its general design, but its usability has not yet been tested 
(Cui et al., 2016). 
 
 
• Recruit: Ontology-based information retrieval system 
 
Recruitment in clinical trials faces many challenges as the recruiting target is rarely achieved and 
even when it is achieved, it is highly time-consuming. After recognizing this problem, Patrão et 
al. introduced an information retrieval system which will be able to screen patients, i.e., find 
them based on clinical criteria. This system is called Recruit and is based on the Electronic Health 
Record (EHR) data (2015). 
Recruit consists of two parts: the backend part, which extracts, transforms and indexes data and 
the frontend part, i.e., a web interface for the user to use the system. The backend combines 
structured and unstructured data from the original databases and provides an index. Afterwards, 
the frontend queries the search engine (Apache Solr) which processes the index (Patrão et al., 
2015).  More specifically, Patrão et al. (2015) developed an ontology-based data warehouse and 
proceeded with importing this data in an indexing server; this data is considered structured 
metadata. And they were imported along with unstructured report texts. First, data from several 
structured databases were integrated into a triple store endpoint (Openlink Virtuoso) (Figure 19). 
Afterwards, the triple store endpoint was enriched by a set of SPARQL queries (Patrão et al., 
2015).    
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Figure 19. Integration process dataflow (Patrão et al., 2015). 
Second, structured (presented as an ontology) and unstructured data were integrated and 
published into a search engine (Figure 20) (Patrão et al., 2015).   
 
Figure 20. Search engine publishing dataflow (Patrão et al., 2015). 
 
An important advantage of this system is that the system will evaluate the way that users use it 
and will be strict with the patient data access (Patrão et al., 2015).   
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• SemEHR: “an open source semantic search and analytics tool for EHRs” 
Another information system aiming to support recruitment was introduced by Wu et al. (2018). 
According to them, SemEHR is “a semantic search and analytical system that generates a 
complete and process- able view of patients from their clinical notes”.  
As shown in Figure 21, three subsystems are combined in order to develop SemEHR: 
§ The production subsystem, which extracts unstructured (free-text) clinical notes from 
heterogeneous EHRs. For this function to be performed, data retrieval, information 
extraction and semantic indexing ought to be done. For the data retrieval step to be 
concluded, a harmonization tool for EHRs is used (called CogStack). This tool homogenizes 
the distributed data which are in heterogenous formats. Each document flows from the 
data retrieval step into an NLP pipeline and the extracted documents are afterwards 
analyzed during the semantic indexing step. The analysis results are, then, indexed by an 
Elasticsearch cluster. The final result is the development of patient-level summaries which 
are constantly updated whenever a new document is added to the index. 
§ The continuous learning subsystem, which continually addresses study-specific matters. 
Feedback from users is collected and after it is analyzed, two elements are used in order 
to optimize the Information Extraction (IE) results: a rule engine (creates and applies rules 
for removing results that are not wanted) and a machine learning engine (calculates the 
value of each concept mention, according to user feedback). 
§ The consuming subsystem, which consists of components that will use IE results and 
clinical knowledge in order to support tasks, such as trial recruitment. Each consuming 
task is called “study” and is stored in the SemEHR’s Study Knowledge Graph (KG) along 
with all the “study’s” parameters (Wu et al., 2018). 
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Figure 21. The SemEHR architecture (Wu et al., 2018). 
 
§ Ontology-Based eXtensible (OBX) data model: a framework for clinical research data in 
the Immunology Database and Analysis Portal (ImmPort). 
Kong et al. (2011) realized the need for the development of a mechanism which will help with 
the re-use and re-analysis of clinical research data. Therefore, based on the Basic Formal 
Ontology (BFO) (BFO, 2019) and the Ontology for Biomedical Investigation (OBI) (The OBO 
Foundry, 2019), Kong et al. built the Ontology-Based eXtensible data model (OBX); this ontology 
will support the Immunology Database and Analysis Portal (ImmPort) (2011). 
The main component of the data model is the Event Table which provides information regarding 
events (planned or not) that actually happened (actual events). As shown in Figure 22, each event 
can be related with its study design, the time context of its occurrence and one or two objects. 
Furthermore, a planned event can be described by the Procedure Specification subclass and more 
information regarding its protocol will be presented (Kong et al., 2011). 
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Figure 22. OBX conceptual model representation (Kong et al., 2011). 
Afterwards, and based on the OBX core conceptual model, Kong et al. developed a framework 
which presents some of the specific members of the entities in Figure 22. The entities presented 
in the framework are of great importance to the ImmPort clinical research database. The class 
types and subtypes of the entities are shown in Table 3. Each subtype contains certain attributes 
(e.g., name, type, time, duration etc.) (2011).  
Table 3. Class types and subtypes in OBX model (Kong et al., 2011). 
 
The outcome of this ontology-based model is the creation of a database schema which will enable 
the storage and collection of diverse clinical research data originated from studies in several 
domains and sites. Moreover, OBX provides to researchers the opportunity to integrate clinical 
data (CRF data) and mechanistic experiment data (type of Assay). Finally, this model offers the 
Class Types Subtypes Inputs Outputs
Object Population, Human subject, Biological sample, Animal subject, Compound or Agent, Complex compound, Environment factor, Site, Software, Instrument, Manufacturer.
Biomaterial Transformation
Subject biomaterial transformation, Substance biomaterial transformation, Substance 
merging biomaterial transformation, Biosampling process, Surgery process, Device 
intervention process, Environmental exposure process.
Events with 
one or more 
biomaterials
Events with 
one or more 
biomaterials
Assay
Subject assessment (Medical history, Family history, Questionnaire), Subject inclusion-
exclusion, ECG, Adverse Event, Primary result, Biological sample, Human subject, Lab test 
or Measurement of analyte.
Events with 
one or more 
biomaterials
Data
Data Transformation
Diagnostic process, Study reported premature termination, protocol deviation, Research 
data analysis (Baseline and Outcome measurement process), Derived result (Diagnosis 
result).
Data Data
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advantage of data sharing and system interoperability from ImmPort database to other 
organizations using it (Kong et al., 2011). 
 
§ The ObTiMA system: Ontology-based managing of clinical trials (Design clinical trials and 
manage the patient data within them). 
In 2010, Stenzhorn et al. developed an Ontology-based Trial Management Application (ObTiMA). 
The data management of this system is based on a master ontology and a semantic mediator, 
while the system’s main components are the Trial Builder and the Patient Data Management 
System (Fig. 23). Stenzhorn et al. (2010) describe these four components as follows: 
• Master Ontology 
In this ontology concepts regarding research on cancer are presented. According to Stenzhorn et 
al., although the ontology is focused on the cancer domain, not many limitations can be found 
over its reusability in other domains; cancer is a field with a vast amount of entities and processes 
(2010). Therefore, and as the master ontology contains information regarding genetics, 
administration and legal requirements, it might be able to be used in other research domains, as 
well (Stenzhorn et al., 2010). 
• Semantic Mediator 
During semantic mediation, information from different data sources is matched, combined and 
retrieved. This process is characterized as “semantic” because the databases are developed with 
Master Ontology concepts and relations. Moreover, an ObTiMA’s database can be used as a data 
source to the mediator (Stenzhorn et al., 2010). 
• Trial Builder 
A clinical trial consists of several aspects (as presented in Chapter 1) and the trial builder enables 
the ObTiMA’s user to specify them. For example, via a master protocol the trial’s outline can be 
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described and treatment plans and their time-order can be graphically presented. For collecting 
the information regarding a treatment, a Case Report Form (CRF) ought to be created at every 
stage of the treatment plan. The CRFs are developed based on the Master Ontology and present 
integrated information in the shape of a graphical user interface; the result is the creation of a 
trial database. The first step is called Ontology View and the user creates a CRF item by selecting 
concepts from the ontology – the master ontology aims to be less detailed than the clinicians’ 
meticulous points of view. Each concept selection will lead to the presentation of its relative 
concepts. The next step (Item Editor) begins after the concept is chosen and presents the 
concept’s attributes, e.g., answer possibilities or data type. The final step is called Preview Items 
and demonstrates the items created in the preceding steps in the exact order that they should 
be presented on the CRF. If needed, this order can be changed manually (Stenzhorn et al., 2010). 
Moreover, another outcome is the development of a CRF Repository. As the CRFs are developed 
based on the Master ontology and share the same terminologies, existing CRFs can be stored and 
reused in other clinical studies (Stenzhorn et al., 2010). 
• Patient Data Management System (PDMS) 
This system is automatically developed (and not manually) based on the Trial Builder and more 
specifically on the master protocol and CRFs created during the Trial Builder. Via PDMS, clinicians 
can find the help they need in order to follow-up each patient’s treatment plans and fill the CRF 
with information over the treatment status. An advantage of this system is the feedback it 
provides regarding every new entry of information and therefore, errors are displayed and 
explained. Furthermore, ObTiMA participates in the data exchange between distributed clinical 
settings; hence, trial metadata, CRF descriptions and patient data can be imported and exported 
from the system. Finally, as the system was developed with the goal to integrate data from 
different clinical trial sites, security regarding legal and ethical requirements must be taken into 
consideration. In order to guarantee data security, ObTiMA uses two different database servers: 
one for personal data and another one for data collected during research (Stenzhorn et al., 2010). 
 63 
 
Figure 23. The ObTiMA System Components (Stenzhorn et al., 2010). 
 
 
• RCT Schema: a trial ontology for trial interpretation and application to clinical care. 
Randomized Clinical Trial (RCT) knowledge bases are “trial banks” which have systematic 
reviewing as their target task. For managing systematic reviewing, the information needed is the 
sum of recommendations regarding a trial report’s components: information about trial design, 
trial execution and trial results. The RCT ontology was developed and evaluated with the 
competency decomposition method developed by Sim, Olasov and Carini (2004), i.e., each task 
is hierarchically divided into subtasks and information regarding the completion of each task is 
delineated in order to determine the ontology components (Sim, Olasov and Carini, 2004). 
Table 4. Examples of trial information modeled in RCT Schema (Sim, Olasov and Carini, 2004). 
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As shown in Table 4, RCT Schema provides information over a trial’s administration, design, 
execution and results, as well as, over their subclasses. More specifically: 
• The TRIAL class can be described by the MAIN-STUDY and SECONDARY-STUDY classes, 
each of which contain information regarding clinical and scientific background, 
publication and administrative data, etc.  
• The PROTOCOL class is another way to describe the study classes above. This class consists 
of two categories, the INTENDED-PROTOCOL and the EXECUTED-PROTOCOL. The 
information provided by this class describes the study design, the subject inclusion 
criteria, recruitment, randomization, follow-ups, adverse events, etc. 
• The SAMPLE-SIZE-CALCULATION class is the one that describes the statistical design of a 
MAIN-STUDY. 
• The POPULATION class (name, size, age and gender) is divided into three subclasses: 
RECRUITED-POPULATION (its subclasses refer to screened, eligible, enrolled and 
randomized subjects), EXCLUDED-POPULATION (its subclasses refer to screened but not 
eligible, eligible but not enrolled, enrolled but randomized and randomized but excluded 
from intention-to-treat analysis subjects) and ANALYZED-POPULATION.  
• AGE-GENDER-RULE class. 
• ETHNICITY-LANGUAGE-RULE class. 
• CLINICAL RULE class (number of subjects agreeing or not to this rule): its subclasses are 
RECURSIVE-RULE and BASE-RULE (UMLS terminology describes these rules). 
• The INTERVENTION-ARM class (UMLS terminology is used). This class is described by other 
information regarding the type of intervention, i.e., device, drug, procedure, other 
intervention (EXPERIMENTAL-ARM class). Moreover, the COMPARISON-ARM class can be 
the EXPERIMENTAL-ARM, PLACEBO, USUAL CARE and NO-TREATMENT classes. 
• The OUTCOME class: PRIMARY-OUTCOMEs, SECONDARY- OUTCOMEs, BASELINE-
CHARACTERISTICS, SIDE-EFFECTS and OUTCOME-ASSESSMENT class. For each outcome, 
information can be described by the STATISTICAL-ANALYSIS-AND-RESULTS class and the 
REGRESSION-ANALYSIS-AND-RESULTS class (Sim, Olasov and Carini, 2004). 
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It is crucial to establish a standardized clinical vocabulary in order for the RCT Schema to be 
efficient and useful. The more terms included in the vocabulary, the more useful the information 
system will be (Sim, Olasov and Carini, 2004). 
Although Sim, Olasov and Carini (2004) developed this ontology in order to improve evidence-
based clinical care and practice, it seems like this system might be able to support the first step 
of a clinical trial: Conceiving the research question. With the developed tasks and subtasks, a 
systematic review of text-based publications of clinical trials can be less time-consuming, 
especially if investigators stored their findings into knowledge bases that can be understood by 
computers (2004). 
 
§ Patient Clinical Data (PCD) Ontology: Classifying and organizing information. 
In 2018, Boshnak et al. built the Patient Clinical Data (PCD) Ontology. According to them, the 
development of the PCD ontology aims at the representation of clinical data related to Electronic 
Health Records (EHR). These clinical data are collected during patient visits, present a patient’s 
health status and their accurate representation via PCD will enable researchers and other clinical 
professionals to have adequate information on a patient’s condition. For building the PCD 
ontology, the first step is the specification of the goal of the ontology (collecting data). The 
second step is called “Knowledge Acquisition” and its sub-steps are: (a)study clinical terms in an 
informal way, (b) build the Glossary of Terms (GT) of clinical concepts in a formal way (via unified 
medical language systems-UMLS), (c)integrate the medical ontologies, create classes, subclasses 
and their relationships and classify the clinical/medical terms into classes, (d) evaluate the PCD 
ontology by interviewing physicians and other EHR users. During the third step of the PCD 
ontology building, “Conceptualization”, the stages are: (a) develop the Glossary of Terms (GT) of 
PCD Ontology by using UMLS (Fig. 24), (b) define and organize classes (cluster synonymous terms 
and link concepts – use the combination approach: top-down and bottom-up approach), (c) 
develop the concept dictionary (concept name, class attributes, relations), (d) define table of 
class attributes (the table should include defined concept, attribute name, value type, cardinality 
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and for defining the table Fast Healthcare Interoperability Resources – FHIR (HL7.org, 2018)– is 
used), (e) develop the Conceptual Model of PCD Ontology (Fig.  25) (Boshnak et al., 2018). 
 
 
Figure 24. The UMLS source vocabularies used in the PCD ontology (Boshnak et al., 2018). 
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Figure 25. The Conceptual Model of the PCD Ontology (Boshnak et al., 2018). 
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“Integration” is the fourth step of building the PCD ontology and it includes looking for concepts 
in the UMLS, importing classes of interest from the system and integrating these classes with the 
PCD ontology. The fifth step is “Implementation” and the outcome is the coding of the ontology 
which will lead to a formal ontology development language (Boshnak et al., 2018). 
The final outcome of the PCD Ontology is the classification of information. The main classes of 
this ontology are: Patient, Encounter, Findings, Diagnosis, Procedures, Medications, Operations 
and Diagnostic tests (Table 5). Moreover, the ontology provides a section called “Properties”, 
which is divided into object properties (32) and data properties (170). The former properties 
describe the connection between two objects (e.g., a patient has a disease), while the latter 
properties provide information about an object and its data (e.g., an address, an emergency 
contact, etc.) (Boshnak et al., 2018). 
 
Table 5. Patient Clinical Data (PCD) Ontology: Classes and Information provided by each class (Boshnak et al., 2018). 
 
 
Classes Description - Information provided
Patient Provides demographic and clinical data gathered for each patient.
Encounter Provides information about every contact between patient and provider. Information about patient type, location, specialty, physician, appointment, hospitalization, patient registration.
Findings Provides information about activities during the encounter between apatient and a physician, e.g., history regarding a patient's complaints, symptoms, vital signs, allergies, immunizations, general and local examination.
Diagnosis
Includes patients' diseases and conditions (the classification is based on the International Classification of Diseases Tenth Revision - ICD10). Its 
subclasses (19) are the main types of diseases. Information provided by this class: patient's condition, clinical status, the severity of a patient's 
condition according to the clinician's assessment, the start date of the disease, notes regarding clinical decision.
Procedures Consists of 5 subclasses. Each subclass is a type of a procedure determined by the clinician according to the examination and diagnosis process.
Medications Consists of 35 subclasses. For each drug, information regarding treatment plans and instructions is provided.
Operations Provides information about a patient's performed operations, the attending and responsible medical/clinical stuff, the operation equipment, the preoperative and postoperative diagnosis, etc.
Diagnostic 
tests Consists of radiology (17 subclasses) and laboratory (18 subclasses) tests.
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The two final steps of building the PCD Ontology are “Evaluation” (the ontology ought to be 
consistent and the patient clinical data ought to be valid) and “Documentation” (for enabling the 
use and re-use of the ontology) (Boshnak et al., 2018). 
Patient Clinical Data (PCD) Ontology provides a platform in which clinical data can be organized, 
and therefore, retrieved by healthcare professionals. Although Boshnak et al. proposed this 
ontology for better clinical decision making and access by researchers and other healthcare 
professionals, this ontology seems adequate to be used for better tracking of clinical trials 
participants, especially if this ontology is used by as many clinical trial settings as possible. With 
the PCD Ontology, clinical data saved in the EHRs (e.g., from study visits and follow-up visits) can 
be accessible and usable by investigators and therefore, investigators will be able to be fully 
aware of each participant’s health status and compliance (physically and psychologically). 
Moreover, the recruitment process might become less time-consuming, because of the common 
Glossary of Terms and the connection between all the classes mentioned above, as provided by 
the PCD Ontology (2018). 
 
• The Semantic Electronic Health Record (SEHR) ontology 
 
The Semantic Electronic Health Record (SEHR) ontology is based on the PPEPR Methodology 
(Sahay, Akhtar and Fox, 2008) (Fig. 26) and its development is a step of the Linked2Safety EU 
project. Analysis of the Linked2Safety project was provided above, but a brief summary is 
presented at this point. Linked2Safety aims at the development of a platform for patient 
recruitment across European clinical trials units and a global clinical terminology which will 
include and integrate several local terminologies, “a consistent, unambiguous and unifying 
framework of terminology”. Therefore, the SEHR ontology is presented as a solution to 
distributed clinical sites (Sahay et al., 2011). 
Based on the PPEPR Methodology for building an ontology, SEHR ontology proceeds with an 
alignment of local and global ontologies by using three approaches (independently or in 
combination) for adapting the local concept. The first approach is called “Top-Down” and 
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suggests a specialization of the global ontology in order for global concepts to resemble local 
ones. The second approach, the “Bottom-Up” approach, includes an extension of the local 
ontology and its generalization in order for local concepts to resemble global ones. Finally, the 
“Middle-Out” approach (the third approach) proposes the development of an additional 
specialized class similar to the concepts. In other words, SEHR ontology is a clinical trial ontology 
which aims at the layering and adaptation of clinical terminologies. During the layering step, 
global and local ontologies are processed, and the result is the production of layered ontologies 
and the arrangement of the ontologies into global and local spaces. During the adaptation step, 
after the local and global ontologies are processed, the outcome is an extended version of layered 
ontologies which is adapted to the local requirements. Hence, clinical trial data integration is 
more feasible (Sahay et al., 2011). 
 
 
Figure 26. PPEPR Ontology Building Methodology (Sahay et al., 2011). 
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Evaluation and Categorization of Information Systems and 
Ontologies in Clinical Research 
 
 
 
Information systems have been researched and introduced in the healthcare sector and have 
offered benefits throughout many processes. It is important, though, that each healthcare 
information system should be evaluated, and according to Friedman and Wyatt (1997) and 
Odhiambo-Otieno (2005) this evaluation is necessary for at least five reasons. First, by evaluating 
information systems, healthcare professionals become more acquainted with the idea of a cost-
effective and safe way of managing data (“promotional” reason). Second, scholars will continue 
their research on more accurate and effective information systems (“scholarly” reason). Third, 
via the evaluation process, mistakes from previous systems are presented and the more effective 
methods are pointed out (“pragmatic” reason). Fourth, healthcare professionals can measure the 
safety in correspondence to the cost and therefore, be ethical (“ethical” reason). Last, evaluation 
can prove another aspect of the effectiveness of a system which is the accuracy of the 
information provided to healthcare professionals (“medicolegal” reason). Hence, before 
proceeding with the establishment and use of an information system, one or more of the above 
aspects should be considered and the healthcare professionals should decide accordingly.  
According to Crepaldi et al. (2018), a complete Health Information System (and therefore, Clinical 
Research Information Systems and Ontologies) should be evaluated according to five pillars: “the 
perspective of patients, health professionals, software engineering, security and safety, and 
managerial issues”. Many other researchers would agree with Crepaldi et al. on the points about 
the evaluation of staff satisfaction (Gugerty, Maranda and Rook, 2006; Hanmer, 1999; Wang and 
Yang, 2007), the evaluation of security and safety being extremely important (Low and Chen, 
2012; Smith et al., 2011) and about the assessment of managerial issues, such as quality, validity, 
economics, efficiency and effectiveness and flexibility (Hanmer, 1999; Low and Chen, 2012; 
Odhiambo-Otieno, 2005; Richesson and Andrew, 2019; Smith et al., 2011; Wang and Yang, 2007). 
In addition to the criteria mentioned above, two crucial criteria, common in the perspectives and 
suggestions of all the mentioned researchers, is usability (or easy-to-use ability) and functionality 
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(it includes: security and confidentiality, data consistency and health information standards, 
appropriateness and accessibility and user acceptability) (Hanmer, 1999; Richesson and Andrews, 
2019).  
Moreover, according to Park et al. (2018), information systems used in clinical trials should be 
able to support one or more than one steps and phases of a clinical study’s process and one or 
more than one therapeutic/disease areas. Also, information systems should be characterized 
according to their access protocols, their data’s safety and security, their “controlled vocabulary”, 
their relation or not with existing databases, such as Electronic Health Records (EHRs) and 
Hospital Information Systems (HIS) and their application or not of a notification system, such as 
a notification system which will send notifications whenever a patient is eligible for a clinical 
study’s recruitment (Park et al., 2018). 
Therefore, according to this literature review over the evaluation and categorization of clinical 
information systems and clinical research information systems and to some conclusions made 
after reviewing the clinical research process, information systems and ontologies, the criteria 
designated in order to evaluate and categorize these information systems (IS) are:  
 
• Usability (easy-to-use system) 
• Flexibility, Scalability  
• Accessibility (Authorized or open-to-the-public access) 
• Data Security/Safety/Privacy 
• Data quality (accuracy, consistency, agreement with health information standards) 
• Automation 
• Standardized vocabulary/terminology 
• Ability to support multi-centered trials 
• The clinical study’s step(s) the IS can support 
• The clinical study’s phase(s) the IS can support 
• The study design type(s) the IS can support (Observational/ Interventional) 
• The therapeutic/disease area(s) the IS can support 
• The category(/-ies) of clinical research data the IS can provide 
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• The IS’s relation to other databases (e.g., HER or HIS) 
• The application of a notification system, e.g., alerts for eligible patients. 
 
Unfortunately, due to restricted information regarding staff and patient satisfaction, evaluation 
based on these criteria will not be presented (despite their being important attributes for Clinical 
Information Systems assessment). 
Evaluation and categorization of the information systems, ontology-based information systems 
and ontologies analyzed in this thesis are presented in the tables below (Tables 6-11).  The 
evaluation and categorization were performed based on the criteria mentioned above. 
 
Table 6. Evaluation of the information systems regarding data security/safety/privacy and data quality. 
 
Data Security/Safety/Privacy Data Quality
Tools in a CIS Needs evaluation Needs evaluation
CDW-CIS Yes (Anonymization) Yes (it is used for quality management)
COATI Yes (patients numbers are used) Yes (GCP Guidelines)
HIS-based patient recruitment Yes Yes (supports quality management)
Single Source IS
Yes (access is controlled, but needs 
imporovement and approvals - data protection 
issues need to be observed strictly)
Mechanisms for quality control and validation 
will be provided
CRDW Yes No (Restricted)
ISCO Yes Yes (quality control tool)
AEDAMS Yes Yes (quality checks, improved data quality)
Active Computerized Pharmacovigilance Unclear Medium 
National Clinical Trials Registry Yes (patient data is not provided by the registry - only information regarding the study is provided)
Yes (data validation, but data should be 
monitored and improved at all times
OpenTrials
Yes (secure patient data access via 
ClinicalStudyDataRequest.com and other 
databases)
Yes
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Table 7. Evaluation of the ontology-based information systems and ontologies regarding data security/safety/privacy and data 
quality. 
 
 
 
 
 
 
 
 
 
Data Security/Safety/Privacy Data Quality
Epoch Yes Yes (tracking of data)
OnWARD Yes (Role-based acces control mechanism) Yes (Input Validation)
A semantic interoperability layer Yes (Filtered data based on the user - in the future) Adequate
The Linked2Safety project Yes ("closed-world" room) Yes (Quality Control)
ODaCCI Yes  (access only to de-identified patient data) Yes (automatic data validity checks)
Recruit Yes  (Strict patient data access) Unclear
SemEHR Unclear Yes (accuracy)
OBX No Unclear
ObTiMA Yes (security architecture) Increased, but needs improvement
RCT Schema Unapplicable (it is an ontology) Yes (the otology is competent for the tasks responsible for)
PCD Ontology Unapplicable (it is an ontology) Unclear
SEHR Ontology Unapplicable (it is an ontology) Yes (quality control - SEHR is part of the Linked2Safety project)
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Table 8. Evaluation of the information systems. 
 
 
 
 
 
 
Usability Flexibility/Scalability Accessibility Automation Standardized Vocabulary/Terminology The IS’s relation to other databases (e.g., EHR or HIS or CIS, etc.) The application of a notification system
Tools in a CIS Yes (increased usage of the system) No (only hospitals with the same CIS) Access to trial registry: resrtricted to selected trial coordinator
Automated alerts / Automated reports 
editing/ not automated electronic 
transcripts from the CIS to trial databases
Unclear Tools are implemented on CIS Yes (hospital sdmission alerts)
CDW-CIS Yes Unclear Authorized Unclear Unclear Extracts data from EHRs and CISs No
COATI Yes (by people familiar to clinical trials) Yes Via the World Wide Web Not complete Yes None No
HIS-based patient 
recruitment Yes No Authorized Yes Unclear Yes (HIS-based) Yes (electronic alerts)
Single Source IS Yes (the HIS is used) Yes (every hospital is responsible for its HIS)
Physicians and nurses: access to the HIS      
Study data management team: access to 
the clinical research database
Automatically and manually used system No (different terminologies and standards - different HISs) Based on HIS
Yes (automated notification for potential 
trial subjects via email)
CRDW No (uncertainty) Unclear Authorized (via a web interface) Yes Yes (German mostly) Yes (EHR & data are extracted from the CIS) No
ISCO Yes (user support is available and training-time is low) No (too specific) Only to ISCO users Not complete
Yes (data dictionary was developed), but 
standardization of coding systems will be 
needed
Yes (development of the HIS) No
AEDAMS Yes (average training-time is 30 minutes) Yes (scalable to different protocols and to support larger number of events)
Authorized ("users are only granted access 
after verification of their role on the study 
by the administration")
Automation (Automated tool) Yes None Yes (notification is done by automatically generated emails)
Active Computerized 
Pharmacovigilance Unclear Unclear Unclear
Yes (the system can automatically detect 
new adverse events by using only the 
existing information in EHR systems)
Yes (MedLEE: Medical Language, Etraction 
and Encoding system)
"Applied on comprehensive unstructured 
clinical data from EHRs" No
National Clinical Trials 
Registry Yes (easily operated by patients)
Yes (designed for all types of clinical 
studies) Open to the public Automated Yes (vocabulary collection) None No
OpenTrials Yes (user-friendly web interfaces )
Yes ("data that can be freely used, 
modified, and shared by anyone for any 
purpose" - flexible schemas and data 
structures)
Open database Automatically and manually used system
A common dicitionary must be developed - 
For now: wide categories that can be 
interpreted in many ways have been 
introduced
Extracts data from registers No
 76 
Table 9. Evaluation of the ontology-based information systems and ontologies. 
 
 
 
Usability Flexibility/Scalability Accessibility Automation Standardized Vocabulary/Terminology
The IS’s relation to other databases 
(e.g., EHR or HIS or CIS, etc.)
The application of a notification 
system
Epoch No ("cumbersome")                      Yes Authorized (knowledge Base Server - API) Yes Yes None Yes (ImmunoTrak)
OnWARD Yes (minimal training) Yes Authorized (role-based acces control mechanism)
Semi-automatic (automatic data 
validation) Yes (Clinical research ontology) None No
A semantic 
interoperability layer Unclear Yes
Filtered data based on the user - in 
the future
Yes (automated terminology 
binding)
Yes (the system provides a common, 
standardized terminology)
Clinical Trial Management Systems 
(CTMS), Laboratory Information 
Management Systems (LIMS), 
Electronic Health Record (EHR), etc.
No
The Linked2Safety 
project Unclear Yes
Researchers and healthcare 
professionals with access to the 
platform (Authorized)
Yes Yes Analysis and connection of distributed EHRs No
ODaCCI Unclear (Not evaluated) Yes (adaptable due to its general design)
Access only to de-identified patient 
data
Automatically and manually used 
system
Yes (Epilepsy and Seizure Ontology - 
EpSO)
Sometimes data from EHRs are 
used No
Recruit Yes (15 different users/week)
Yes ("its modular design could be 
applied to other clinical conditions 
and hospitals")
Strict patient data access Unclear Yes Extracts data from EHRs No
SemEHR Unclear Yes Unclear Yes Yes Uses data from EHRs No
OBX Unclear Yes (additions can be made easily) Web-based public resource Unclear Yes
Public data repositories (e.g., 
GenBank, UniProt, the Immune 
Epitope Database)
No
ObTiMA
Yes (users do not need to know 
technical details -  straightforward - 
end-user usability was ensured)
Yes (adaptable) Authorized Automated IS Yes (Master ontology) None No
RCT Schema Unclear Yes Unclear Needs to be automated Yes (UMLS - SNOMED CT in the future)) None No
PCD Ontology Yes Unclear Accessible to researchers and healthcare facilities users Unclear
The PCD ontology developes a 
Glossary of Terms (by using UMLS) 
and integrates medical ontologies
Data are related to EHRs No
SEHR Ontology
Medium  (most of the users claim to 
understand the ontology, but 
additional support should be 
provided)
Yes (used in many health care sub-
domains)
Researchers and healthcare 
professionals with authorized access 
to the platform (SEHR is part of the 
Linked2Safety project)
Unclear
The SEHR ontology provides an 
integration of local and global 
ontologies
None No
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Table 10. Categorization of the information systems. 
The clinical study's step(s) the IS can support The clinical study's phase(s) the IS can support The study design type(s) the IS can support (Observational/ Interventional)
The therapeutic/disease area(s) the IS can 
support
The category(/-ies) of clinical research data the 
IS can provide Ability to support multi-centered clinical studies
Tools in a CIS
Step 2: Designing a new study & Step 3: Study 
execution & Step 4: Report Results & Step 5: 
Interpret the results and apply them to clinical 
care and policy
Phase I, II, III/IV Interventional Variety of disease/therapeutic areas
Data for recruitment and adverse events & Data 
from stored specimens, images, etc.  and from 
the medical examinations during the trial & 
Follow-up data  
No
CDW-CIS Step 3: Study execution Phase I, II, III/IV Observational and Interventional Unclear Follow-up data & Data from the process and outcomes of old trials Yes
COATI Step 2: Designing a new study & Step 3:  Study execution & Step 4: Report Results Phase II, III & IV Observational and Interventional Any ("Variety of medical conditions")
Data from the participants’ medical 
examinations during the trial & Data for the 
statistical analysis & Data for adverse events
Yes
HIS-based patient 
recruitment Step 3: Study execution Phase I, II & III Intervnetional
Acute Myeloid Leukemia (AML), neurology, 
dermatology
Data for selection criteria, sampling and 
recruitment Yes (only few centers)
Single Source IS Step 3: Study execution Unapplicable (only for interventional studies) Observational (for now) Prostate cancer & Leukemia-only for recruitment Data for selection criteria, sampling and recruitment No (monocentric studies)
CRDW Step 3: Study execution Phase I, II & III Interventional Neurology (e.g., stroke, epilepsy) Data for selection criteria, sampling and recruitment Yes (only few centers)
ISCO Step 3: Study execution Phase I, II & III Intervnetional Oncology Data for selection criteria, sampling and recruitment &Follow-up data No
AEDAMS Step 3: Study execution Phase I, II, III/IV Observational and Interventional (variety of study designs) Variety of disease areas Data for adverse events Yes (multi-national trials)
Active Computerized 
Pharmacovigilance Step 3: Study execution Phase I, II, III/IV Intervnetional Variety of disease areas Data for adverse events Yes
National Clinical Trials 
Registry
Step 3: Study execution & Step 4: Report Results 
& Step 5: Interpret the results and apply them to 
clinical care and policy
Phase I, II & III Interventional Variety of disease areas
Data for recruitment & Data found in 
publications regarding the trial & Data from the 
process and outcomes of old trials
Yes (information regarding multiple locations is 
provided)
OpenTrials
Step 1: Conceiving the research question & Step 
3: Study execution & Step 4: Report Results & 
Step 5: Interpret the results and apply them to 
clinical care and policy
Phase I, II & III Interventional Variety of disease areas
Data for recruitment & Data found in 
publications regarding the trial & Data from the 
process and outcomes of old trials
Yes ("Where the results on a trial have been 
reported in multiple different places, a 
researcher can rapidly review these side by 
side.")
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Table 11. Categorization of the ontology-based information systems and ontologies. 
  
The clinical study's step(s) it can support The clinical study's phase(s) it can support The study design type(s) it can support (Observational/ Interventional) The therapeutic/disease area(s) it can support
The category(/-ies) of clinical research data it 
can provide Ability to support multi-centered clinical studies
Epoch Step 3: Study execution Phase I, II & III Interventional
Immune-mediated disorders (autoimmune 
diseases, islet, kidney and liver transplantation, 
allergy, asthma)
Follow-up data (tracking patients and clinical 
specimens) & Data Data from stored specimens, 
images, etc.
Yes
OnWARD Step 2: Designing a new study & Step 3:  Study execution & Σtep 4: Report Results Phase II Interventional Heart Biomarker Evaluation in Apnea Treatment 
Data for selection criteria, sampling and 
recruitment Yes (small to medium scale clinical trials)
A semantic 
interoperability layer
Step 2: Designing a new study & Step 3:  Study 
execution & Step 4: Report Results Phase I, II & III Interventional Oncology (Breast Cancer)
Data for selection criteria, sampling and 
recruitment & Data for the statistical analysis Yes
The Linked2Safety 
project Step 3: Study execution Phase III & Phase IV Observational &  Interventional Variety of areas, especially chemoinformatics
Data for selection criteria, sampling and 
recruitment & Data for adverse events in multi-
sited trials
Yes
ODaCCI Step 3: Study execution Phase I, II, III/IV (for ongoing trials) Observational and Interventional Neurological Disorders and Stroke (Epilepsy and Seizures)
Data for recruitment & Data from the 
participants’ medical examinations during the 
trial & Data  for statistical analysis 
Yes
Recruit Step 3: Study execution Phase I, II & III Interventional Oncology Data for recruitment Yes (data from several databases)
SemEHR Step 3: Study execution Phase I, II & III Observational and Interventional Dermatology Disorder, Liver Disease (it has been applied on clinical studies in this areas)
Data for selection criteria, sampling and 
recruitment Yes
OBX Step 1: Conceiving the research question & Step 4: Report Results Phase I & II Observational and Interventional Immunology (Allergy, Infectious Diseases)
Data from stored specimens, images, etc. from 
previous studies & Data from the process and 
outcomes of old trials & Data for adverse events
Yes
ObTiMA Step 2: Designing a new study & Step 3: Study execution Phase I, II, III/IV Intervnetional Oncology (but other domains, as well) Follow-up data Yes
RCT Schema
Step 1: Conceiving the research question & Step 
5: Interpret the results and apply them to clinical 
care and policy
Phase I, II & III Interventional (Randomized Clinical Trials) Already used for cardiology, radiology, geriatrics and psychiatry
Data found in publications regarding the trial & 
Data from the process and outcomes of old trials 
(Data for reporting and analysis)
Unclear
PCD Ontology Step 3: Study execution Phase I, II, III/IV Observational and Interventional Variety of disease areas
Data from the participants’ medical 
examinations during the trial & Data for 
recruitment & Follow-up data & Data regarding 
medicine clinical terms  
Yes
SEHR Ontology Step 3: Study execution (SEHR is part of the Linked2Safety project)
Phase III & Phase IV (SEHR is part of the 
Linked2Safety project)
Observational &  Interventional (SEHR is part of 
the Linked2Safety project)
Cardiovascular disease, Migraine, Psychiatric 
Disorder, Breast Cancer, Diabetes, Genetics, 
Neurology
Data regarding medicine clinical terms and drug 
terms used globally (standardized “dictionaries”) Yes
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Synthesis of the Information Systems (IS) and Ontologies (or 
Ontology-based IS) 
 
 
As the goal of this thesis is the development of a guide for choosing the appropriate information 
systems while conducting a clinical study, a synthesis of the 23 information systems and 
ontologies and ontology-based information systems presented above ought to be done. This 
synthesis will be based on the evaluation and categorization tables shown above (Table 6). 
The first step of the synthesis would be the categorization of the systems according to the study 
design type, study step and therapeutic/disease area each system can support, according to the 
clinical research data it can provide and according to the information system’s ability to support 
multi-centered clinical studies. Due to restricted information regarding the study phase that each 
information system/ontology supports, the systems will not be categorized based on this 
criterion (the study phase(s) that each system supports is presented in the table according to the 
clinical study steps that each system supports and the data it provides). However, it should be 
mentioned that the systems which can be used for phase IV studies (as presented in Chapter 1) 
are: Tools in a CIS, CDW-CIS, AEDAMS, Active Computerized Pharmacovigilance, ObTiMA and PCD 
Ontology, according to the data they provide, and Linked2Safety, COATI and SEHR, according to 
the literature. 
 
Categorization according to study design type(s) the IS or ontology can support (Tables 10 & 
11) 
This categorization was accomplished based on the studies that the information systems and 
ontologies have been used. However, an information system or ontology which contains and 
provides data for a clinical trial might, also, be able to provide data for an observational study 
and vice versa, because both categories of clinical studies are in need of almost the same data. 
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§ Information Systems and ontologies supporting both Observational and Interventional 
Studies:  
CDW-CIS, Linked2Safety, ODaCCI, a Database System (COATI/PANDA/DART), SemEHR, OBX, 
AEDAMS, PCD Ontology, SEHR Ontology 
§ Information Systems and ontologies supporting only Observational Studies:  
Single Source IS. 
§ Information Systems and ontologies supporting only Interventional Studies (clinical trials):  
Tools in a CIS, Epoch, OnWARD, a Semantic Interoperability Layer, HIS-based Recruitment, CRDW, 
Recruit, ISCO, Active Computerized Pharmacovigilance, ObTiMA, RCT Schema, National Clinical 
Trials Registry, OpenTrials.  
 
Categorization according to study step(s) the IS or ontology can support (Tables 10 & 11) 
This categorization was achieved based on personal opinion which was shaped based on the 
information provided by each system; in order for an information system/ontology to support a 
study step, certain data must be included. 
§ Step 1. Conceiving the research question 
OBX, RCT Schema, OpenTrials. 
§ Step 2. Designing a new study 
Tools in a CIS, OnWARD, a Semantic Interoperability Layer, a Database System 
(COATI/PANDA/DART), ObTiMA. 
§ Step 3. Study execution 
Tools in a CIS, Epoch, OnWARD, a Semantic Interoperability Layer, CDW-CIS, Linked2Safety, 
ODaCCI, a Database System (COATI/PANDA/DART), HIS-based Recruitment, Single Source IS, 
CRDW, Recruit, SemEHR, ISCO, AEDAMS, Active Computerized Pharmacovigilance, ObTiMA, 
OpenTrials, PCS Ontology, SEHR Ontology. 
§ Step 4. Report Results 
Tools in a CIS, OnWARD, a Semantic Interoperability Layer, a Database System 
(COATI/PANDA/DART), OBX, National Clinical Trials Registry, PCD Ontology. 
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§ Step 5. Interpret the results and apply them to clinical care and policy 
Tools in CIS, RCT Schema, National Clinical Trials Registry, OpenTrials. 
 
Categorization according to disease/therapeutic area the IS or ontology can support (Tables 10 
& 11) 
This table’s element was completed based on the disease/therapeutic areas that the information 
systems and ontologies have been used with. In some cases, it was mentioned in the literature 
that a variety of disease areas can be supported, while in some other cases no information 
regarding the disease area was provided (unclear).  
§ Variety of disease areas: Tools in a CIS, Linked2Safety, a Database System 
(COATI/PANDA/DART), AEDAMS, Active Computerized Pharmacovigilance, National 
Clinical Trials Registry, OpenTrials, PCD Ontology. 
§ Immunology: Epoch (Immune-mediated disorders), OBX (allergy, infectious disease). 
§ Heart Biomarker Evaluation in Apnea Treatment: OnWARD. 
§ Oncology: a Semantic Interoperability Layer (Breast Cancer), HIS-based Recuitment 
(AML), Single Source IS (prostate cancer, leukemia), Recruit, ISCO, ObTiMA, SEHR 
Ontology (breast cancer). 
§ Neurology: ODaCCI (epilepsy, seizures), HIS-based Recruitment, CRDW (stroke, epilepsy), 
SEHR Ontology (migraine). 
§ Dermatology: HIS-based Recruitment, SemEHR. 
§ Liver Diseases: Epoch, SemEHR. 
§ Cardiology: RCT Schema, SEHR Ontology (cardiovascular disease). 
§ Radiology: RCT Schema. 
§ Geriatrics: RCT Schema. 
§ Psychiatry: RCT Schema, SEHR Ontology. 
§ Diabetes: SEHR Ontology. 
§ Genetics: SEHR Ontology. 
§ Unclear: CDW-CIS 
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Categorization according to the category(-ies) of clinical research data the IS or ontology can 
support (Table 10 & 11) 
§ Data for selection criteria, sampling and recruitment 
Tools in a CIS, OnWARD, a Semantic Interoperability Layer, Linked2Safety, ODaCCI, HIS-based 
Recruitment, Single Source IS, CRDW, Recruit, SemEHR, ISCO, National Clinical Trials Registry, 
OpenTrials, PCD Ontology. 
§ Data from stored specimens, images, etc. from previous studies 
Tools in a CIS, Epoch, OBX. 
§ Data for adverse events 
Tools in a CIS, Linked2Safety, a Database System (COATI/PANDA/DART), OBX, AEDAMS, Active 
Computerized Pharmacovigilance. 
§ Data regarding medical and clinical terms and drug terms used globally (standardized 
“dictionaries”) 
PCD Ontology, SEHR Ontology. 
§ Data found in publications regarding the trial 
RCT Schema, National Clinical Trials Registry, OpenTrials. 
§ Data from the process and outcomes of old trials 
CDW-CIS, OBX, RCT Schema, National Clinical Trials Registry, OpenTrials. 
§ Follow-up data 
Tools in a CIS, Epoch, CDW-CIS, ISCO, ObTiMA, PCD Ontology. 
§ Data from the participants’ medical examinations during the trial 
Tools in a CIS, OdaCCI, a Database System (COATI/PANDA/DART), PCD Ontology. 
§ Data for the statistical analysis 
A Semantic Interoperability Layer, ODaCCI, a Database System (COATI/PANDA/DART). 
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Categorization according to the information system’s and ontology’s ability to support multi-
centered clinical studies (Table 10 & 11) 
§ Information Systems supporting multi-centered clinical studies 
Epoch, OnWARD (small to medium scale), a Semantic Interoperability Layer, CDW-CIS, 
Linked2Safety, ODaCCI, a Database System (COATI/PANDA/DART), HIS-based Recruitment (only 
few centers), CRDW (only few centers), Recruit, SemEHR, OBX, AEDAMS, Active Computerized 
Pharmacovigilance, ObTiMA, National Clinical Trials Registry, OpenTrials, PCD-Ontology, SEHR 
Ontology 
§ Information Systems unable to support multi-centered clinical studies 
Tools in a CIS, Single Source IS, ISCO 
§ Unclear: RCT Schema 
 
The evaluation of the information systems should be initiated by not selecting the systems and 
ontologies that do not achieve data quality and data security/safety/privacy requirements 
(Tables 6 & 7). This choice is based on the ICH-Good Clinical Practice (GCP) guidelines for clinical 
research, which emphasize the necessity of quality control which “should be applied to each 
stage of data handling to ensure that all data are reliable and have been processed correctly” 
(International Conference of Harmonization, 1996). Moreover, according to the ICH-GCP 
Guidelines, only authorized and secure data access should be allowed, approval for data changes 
must be given, data ought to be characterized by accuracy, and records that can identify subjects 
must remain secure for privacy matters (1996). More specifically, and as the guidelines for Good 
Clinical Practice claim, “Compliance with this standard provides public assurance that the rights, 
safety and well-being of trial subjects are protected, consistent with the principles that have their 
origin in the Declaration of Helsinki, and that the clinical trial data are credible” (ICH Expert 
Working Group, 1996). In some cases, these criteria were not mentioned in the literature 
(unclear) and these systems will not be included in this evaluation. Therefore, the information 
systems and ontology-based information systems with both data quality and data 
security/safety/privacy assurance, as shown in Tables 6 and 7, are: Epoch, OnWARD, a Semantic 
Interoperability Layer (adequate data quality), CDW-CIS, Linked2Safety, ODaCCI, a Database 
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System (COATI/PANDA/DART), HIS-based Recruitment, Single Source IS, ISCO, AEDAMS, ObTiMA 
(increased data quality, but needs improvement), National Clinical Trials Registry and OpenTrials. 
The next step is to evaluate the above information systems and the three ontologies (RCT 
Schema, PCD Ontology and SEHR Ontology) based on their usability, flexibility/scalability, 
automation and terminology/vocabulary used (standardized or not) (Tables 8 & 9).  
Usability: From the information systems and ontologies with data quality and data 
security/safety/privacy assurance (presented above), only Epoch might lack in usability as it was 
characterized as “cumbersome”. The level of usability of the Semantic Interoperability Layer, the 
Linked2Safety and the ODaCCI is unclear. 
Flexibility/Scalability: The flexible information systems and ontology-based information systems 
are Epoch, OnWARD, Semantic Interoperability Layer, Linked2Safety, ODaCCI, a Database System 
(COATI/PANDA/DART), Single Source IS, AEDAMS, ObTiMA, National Clinical Trials Registry and 
OpenTrials. The HIS-based Recruitment and the ISCO are not flexible. The flexibility of the CDW-
CIS is unclear. 
Automation: The automated information systems and ontology-based information systems are: 
Epoch, Semantic Interoperability Layer, Linked2Safety, HIS-based Recuritment, AEDAMS, 
ObTiMA and National Clinical Trials Registry. The systems which are used both automatically and 
manually are: ODaCCI, Single Source IS and OpenTrials. The OnWARD is characterized as semi-
automatic. The automation of the Database System (COATI/PANDA/DART) and the ISCO is not 
complete and the level of automation of the CDW-CIS is unclear. 
Standardized Vocabulary/Terminology: The information systems and ontologies with 
standardized vocabularies are: Epoch, OnWARD, Semantic Interoperability Layer, Linked-Safety, 
ODaCCI, a Database System (COATI/PANDA/DART), ISCO, AEDAMS, ObTiMA and National Clinical 
Trials Registry. OpenTrials does not have a standardized vocabulary yet. For the CDW-CIS and the 
Single Source IS, the existence of a standardized vocabulary/terminology is unclear. 
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The information systems and ontologies with unclear information regarding usability, 
flexibility/scalability and standard vocabulary/terminology were excluded from the guidelines. 
According to the categorization and evaluation of the clinical research information systems and 
ontologies above, the guidelines for conducting a clinical study are: 
For clinical trials (or interventional studies): 
Step 1. Conceiving the research question: OpenTrials will provide data found in publications 
regarding a trial and data from the process and outcomes of old trials and researchers will be 
able to proceed with a systematic review and comparisons of older data. The National Clinical 
Trials Registry will provide data from the process and outcomes of old trials, as well. 
Step 2. Designing a new study: OnWARD will help with searching for previously conducted clinical 
studies of interest and offer data for establishing selection criteria, sampling and recruitment, 
while ObTiMA will provide information for designing the study via its Trial Builder component. 
Moreover, the National Clinical Trials Registry will provide data for recruitment. The Database 
System (COATI/PANDA/DART) will offer data for adverse events. 
Step 3. Study execution: Epoch will provide follow-up data and data for the specimens selected 
during the trial (therefore, Epoch will provide to future studies data from specimens from 
previous studies). OnWARD will provide data for selection criteria, sampling and recruitment. 
ODaCCI will provide data from the participants’ medical examinations during the trial and for 
selection criteria, sampling and recruitment. ISCO will provide data for selection criteria, sampling 
and recruitment and follow-up data. ObTiMA will provide follow-up data. OpenTrials will provide 
data for selection criteria, sampling and recruitment and follow-up data. AEDAMS and the 
Database System (COATI/PANDA/DART) will provide data for adverse events. Database System 
(COATI/PANDA/DART) will, also, provide data for statistical analysis and data from medical 
examinations during the trial. The National Clinical Trials Registry will provide data for 
recruitment. 
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Step 4. Report Results: OnWARD, the National Clinical Trials Registry will enable researchers to 
develop reports regarding a clinical study and the Database System (COATI/PANDA/DART) will 
provide data for the adverse events that ought to be reported. 
Step 5. Interpret the results and apply them to clinical care and policy: OpenTrials is a database 
which can provide effectively and correctly available results of clinical trials as it can provide data 
found in publications regarding a trial and data from the process and outcomes of old trials. 
Therefore, researchers will be able to proceed with a systematic review and comparisons of older 
data and maybe, a new research question will be conceived (the cycle will be complete). 
 For observational studies only ODaCCI, Single Source IS (which cannot support multi-centered 
studies), Database System (COATI/PANDA/DART) and AEDAMS can be used. Hence, no guidelines 
can be shaped for a complete observational study. 
Limitations of the information systems and ontologies suggested for completing a clinical study 
are presented in Table 12. 
 
Table 12. Limitations of the suggested information systems and ontologies. 
 
Limitations
Epoch no usability
OnWARD semi-automated
ODaCCI incomplete automation
ISCO no flexibility, incomplete automation
ObTiMA −
National Clinical Trials Registry −
OpenTrials semi-automated, a commond dictionary ought to be developed
AEDAMS −
Database System (COATI/PANDA/DART) usable only for people familiar with clinical trials, incomplete automation
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To sum up, researchers should take advice from the guidelines presented above regarding the 
information systems they should use for completing an interventional clinical trial. Moreover, 
clinical investigators should, also, choose which information system to use according to the 
disease/therapeutic area on which their research is based, such as oncology, neurology, etc. 
Finally, more information regarding the information systems/ ontologies accessibility, relation to 
other databases (EHRs, HIS, etc.) and application of a notification system is presented in Table 6 
for the clinical study management team to select the most appropriate information 
system/ontology for their clinical study. 
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Conclusion, Limitations and Suggestions for Future Research 
 
Guidelines for choosing the appropriate information systems for conducting an interventional 
clinical trial were developed. After categorizing and evaluating 23 information systems and 
ontologies, nine information systems were considered to be adequate for being used in a clinical 
research process (the data quality and data security/safety/privacy requirements were met, and 
“unclear” comments did not characterize them). These information systems are: Epoch, 
OnWARD, ODaCCI (Ontology-guided Data Curation for Multisite Clinical Research Data 
Integration), ISCO (Information System for Clinical Organizations), ObTiMa (Ontology-based Trial 
Management Application), National Clinical Trials Registry, OpenTrials, AEDAMS (Adverse Event 
Data Management System) and Database System (COATI/PANDA/DART).  
In the beginning of this research, the same guidelines for observational studies were to be 
developed, as well. Unfortunately, due to lack of information in the papers used for the synthesis, 
not enough information systems supporting observational studies could be included in the final 
evaluation. However, the study design type (Observational or Interventional) of each system was 
reported based on the clinical study that the system was implemented on and this does not mean 
that the system cannot be used in the other design type, as well; this comment can be considered 
as a limitation of this thesis. Another limitation of this thesis is that the evaluation did not include 
patient-reporting and patient satisfaction (whenever applicable) assessment due to unavailable 
information. 
Insufficient information is a limitation in this thesis, as some papers did not provide adequate 
information regarding the evaluation criteria used in this thesis. Therefore, the information 
systems and ontologies with “unclear” comments in their evaluation were not included in the 
synthesis. Moreover, another limitation was that some papers did not provide information 
regarding the study phase(s), study step(s) and study design type(s) the information system or 
ontology can support. Hence, some information systems and ontologies were categorized based 
on the data they provide and not on the authors’ suggestions (because they were not available). 
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These limitations could be resolved in future work by contacting the authors and creators of 
these information systems and requesting more information regarding the unclear parts of the 
systems’ categorization and evaluation. Due to time restriction, communication with the authors 
was not feasible for this thesis.  
Another suggestion for future work could be the conduction of a systematic review of ontologies 
used in clinical research. Information systems are continually being developed and standardized 
terminologies and vocabularies supporting them are an imperative part of their function. 
Moreover, as many information systems are combined for the completion of a clinical study, a 
specific ontology ought to be able to support all these systems and the disease/therapeutic area 
that the clinical study researches. Therefore, this need of a common ontology seems to be the 
reason for the high number of clinical study ontologies and ontology-based clinical research 
information systems found in the literature and analyzed in this thesis. 
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